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ABSTRACT 
 
Nemaline myopathy (NM) (OMIM 161800, 256030 and 605355) is a rare, 
heterogeneous muscle disorder defined on the basis of ultrastructural abnormalities, i.e. 
nemaline bodies in the muscle fibres. Typical features of NM are muscle weakness and 
hypotonia. Inheritance in the majority of cases is autosomal recessive, although some families 
have been described with an autosomal dominant mode of inheritance. Prior to this study, 
mutations in four different genes encoding thin-filament proteins have been shown to cause 
NM. Mutations in the nebulin (NEB) and the skeletal muscle α-actin (ACTA1) genes are 
common causes of NM, whereas mutations in troponin T1 (TNNT1) and γ-tropomyosin 
(TPM3) genes are rare.  
One of the main objectives of this study was to screen a novel candidate gene, TPM2, 
for mutations causing NM. Mutations in TPM3 had been shown to cause NM, and 
γ-tropomyosin encoded by this gene was known to function in the thin filaments of the muscle 
sarcomere in close proximity to β-tropomyosin. Therefore, we speculated that mutations in 
the β-tropomyosin gene, TPM2, could be causing NM. Mutation analysis of samples from 66 
unrelated patients, using single strand conformation polymorphism analysis and sequencing, 
revealed four polymorphisms and two heterozygous missense mutations in two different 
families. The regions in which the TPM2 mutations were identified are homologous between 
different tropomyosin isoforms expressed in skeletal muscle, and affect amino acids that are 
conserved between species.  
Another main objective of this study was to clarify the molecular basis of nebulin as a 
cause of NM. A prerequisite for this was to elucidate the structure of NEB, which encodes a 
giant structural protein of the skeletal muscle sarcomere. One nebulin molecule spans the 
length of the thin filament. It has been speculated that during myofibrillogenesis nebulin 
might determine the length of the thin filaments. A search through GenBank revealed two 
BAC clones homologous to NEB. Altogether 183 exons were identified in the genomic 
sequence. The translation initiation codon is in exon 3, the stop codon and the 3’UTR in exon 
183. The total length of the genomic sequence spanned by NEB is 249 kb. There are four 
regions with alternatively spliced exons, i.e. exons 63-66, 82-105, 143-144 and 166-177, 
giving rise to a number of different transcripts. These transcripts were studied with the aid of 
RT-PCR, cloning, and sequencing. To study the expression of mouse exons 127 and 128, 
corresponding to human exons 143 and 144, we used quantitative real-time PCR. Exons 
143-144 in humans and 127-128 in mice give rise to two different transcripts varying between 
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muscle types and between muscles at different developmental stages. The lengths of the 
transcripts encoded by exons 63-66 differ between fetal and adult human muscles. Exons 
166-177 express at least twenty different transcripts in adult human tibialis anterior muscle 
alone. Preliminary results indicate that alternative splicing of exons 82-105 also give rise to a 
number of different transcripts. Extensive alternative splicing of NEB may explain why NM 
patients with homozygous truncating mutations, contrary to expectations, show expression of 
the carboxy-terminus of the nebulin protein.  
When this study was initiated mutations in NEB had already been identified as a 
common cause of NM. Screening for new mutations in NEB continued and new disease-
causing mutations were found almost monthly. Single strand conformation polymorphism 
analysis and sequencing were used for mutation screening of the last 42 exons of the gene in 
77 NM patients. Twelve novel recessive mutations were identified in 13 families. Affected 
individuals were homozygous for the mutations in five families and compound heterozygous 
in two, while in the remaining cases only one heterozygous mutation was identified. Most of 
the mutations are predicted to result in truncated or internally deleted proteins. Mutations in 
the differentially expressed exons are expected to reduce the nebulin isoform diversity 
necessary for normal muscle development. 
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INTRODUCTION 
 
 
The term ‘congenital myopathies’ was first used in the 1950s to describe a group of 
muscle disorders characterised by generalised muscle hypotonia and weakness, and 
morphological abnormalities of the muscle fibres (Shy and Magee, 1956). In 1963, Shy (Shy 
et al., 1963), Conen (Conen et al., 1963) and co-workers published the first descriptions of a 
novel form of congenital myopathy characterised by the aggregation of nemaline bodies 
(rods) in the muscle fibres. This disorder became known as nemaline myopathy (NM), the 
name being derived from the Greek word “nema”, meaning thread (Shy et al., 1963).  
Five years earlier, in 1958,  Dr Reye, an Australian pathologist described the 
histological features of a myopathy in a 3-year old boy. Reye noted scattered fibres in which 
“the myofibrils are fractured to form irregularly arranged, rod-like fragments”. Reye 
considered these ultrastructural findings to be unique pathological abnormalities of the muscle 
cell and sent the muscle sections to Dr Denny-Brown in Boston for comment. Dr Denny-
Brown concluded that “though this condition of rupture of myofibrils is probably produced at 
the time of removal of the muscle specimens, it is abnormal in indicating an undue irritability 
of the muscle tissue”. As a result of this correspondence, the rod-like fragments observed by 
Dr Reye were considered to be an artefact. Subsequently, the original photograph taken by Dr 
Reye to show this structural appearance was used as an example of experimental artefact 
(Schnell et al., 2000). In 1981 the patient described by Dr Reye was reviewed. On 
examination by Professor McLeod the patient showed typical features of NM. A third biopsy 
was performed confirming the diagnosis. Later, a point mutation in the α-actin gene was 
identified as the cause of NM in Dr Reye´s patient (Schnell et al., 2000).  
Today NM is divided into six different clinical categories depending on the severity, 
onset and associated features of the disease (Wallgren-Pettersson and Laing, 2000; Wallgren-
Pettersson et al., 1999). Mutations in several different genes, all encoding thin-filament 
proteins, have been shown to cause NM (Durling et al., 2002; Ilkovski et al., 2001; Johnston 
et al., 2000; Laing et al., 1995; Nowak et al., 1999; Pelin et al., 1999; Tan et al., 1999; 
Wattanasirichaigoon et al., 2002). Although the precise mechanisms underlying NM remain 
to be unravelled, knowledge about the genes causing the disorder and the proteins encoded by 
these genes is steadily increasing.  
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REVIEW OF THE LITERATURE 
 
1 Skeletal muscle  
 
Vertebrate musculature is composed of three different muscle types; skeletal muscle, 
cardiac muscle and smooth muscle. Skeletal muscles are voluntary, striated muscles enabling 
movement of the skeleton. These muscles are highly specialised for rapid force production. 
Cardiac muscle is an intermittently contracting, striated, involuntary muscle maintaining the 
blood supply to the organs of the body. Smooth muscles are non-striated, involuntary muscles 
found in the uterus and other parts of the genitourinal tract, vascular system walls and 
digestive tract. 
 
1.1 Development of skeletal muscle 
 
During skeletal muscle development mesodermal precursor cells give rise to committed 
myoblasts that, after proliferation and migration to appropriate sites in the embryo, exit the 
cell cycle, express muscle-specific genes, and fuse into multinucleated myofibres (Pownall et 
al., 2002).   
Members of two transcription factor families play essential roles in the skeletal muscle 
developmental pathway. These are the myogenic regulatory factor (MRF) family and the 
myocyte enhancer factor 2 (MEF2) family of MADS-box transcription factors. There are four 
members of the MRF family i.e. myogenic factor 5 (Myf5), MyoD (myogenic determination), 
myogenic regulatory factor 4 (MRF4) and myogenin (Davis et al., 1987; Emerson, 1990). All 
these transcription factors contain a highly conserved basic helix-loop-helix domain that is 
involved in DNA binding and protein dimerisation (Murre et al., 1989).  
Skeletal muscle development begins with a multistep pathway in which mesodermal 
precursor cells are selected to form myoblasts (Figure 1). In skeletal muscle this process is 
regulated by Myf5 and MyoD (Arnold and Winter, 1998). In vertebrates Myf5 initially 
controls early processes of progenitor specification, including cell proliferation and local cell 
migration, to establish progenitor stem cell pools at sites of myogenesis, whereas MyoD 
functions in the initiation of differentiation and contractile protein gene activation (Pownall et 
al., 2002). In adults, MyoD and probably also Myf5 have additional regulatory functions in 
fibre-type differentiation (Hughes et al., 1993) and satellite cell recruitment for muscle 
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regeneration (Cornelison et al., 2000). Muscle cells have their own intrinsic transcriptional 
program for establishing synapses controlled by MyoD and myogenin (Blais et al., 2005).  
Myogenin, mrf4 and myocyte enhancer factor 2 c (Mef2c), activated by MyoD and 
Myf5, function as transcription factor regulators for muscle protein-specific genes 
(Edmondson et al., 1992; Pin et al., 1997; Yee and Rigby, 1993). Mef2c functionally and 
physically interacts with MRFs through its MADS domain to enhance the transcriptional 
activities of MRFs and thus activate muscle transcription enhancers (Bour et al., 1995; Lilly et 
al., 1995). The contractile protein genes activated during myocyte differentiation include the 
genes for myosin heavy and light chains, desmin, α-actin, nebulin, titin, tropomyosin and 
troponins I, T and C as well as those for proteins involved in synapse formation and calcium 
signalling (Craig and Padron, 2004). The first sign of muscle differentiation is the expression 
of desmin. Subsequently, other proteins participating in myofibrillogenesis appear in a precise 
order (Furst et al., 1989). The kinase domain of titin has recently been shown to control 
muscle gene expression and protein turnover (Lange et al., 2005).  
Small, multinucleated cells known as myotubes are formed when clusters of 
mononucleated myocytes, the post mitotic daughter cells of myoblasts, fuse (Clark et al., 
2002b) (Figure 1).  
 
 
 
 
 
A requirement for this fusion is that the myocytes have withdrawn from the cell cycle 
and initiated differentiation. Cell cycle inhibitor p21 most likely regulates the cell cycle 
Figure 1.  Myoblasts (left) fuse to form multinucleated myotubes (right) during skeletal 
muscle differentiation. Magnified x 100 (from Ahola, 2004) 
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withdrawal (Andres and Walsh, 1996). The primary myotubes formed after fusion are 
100-300 µm long. Further length increases occur by fusion of more myocytes to the 
elongating ends of the myotube or by fusion with other myotubes. These fusions result in 
myotubes that can reach several centimetres in length and contain several hundred centrally 
located nuclei (Clark et al., 2002b). Ca2+ is needed by the N-cadherin molecules on adjacent 
cells to mediate the attachment essential for fusion (Knudsen et al., 1990).  
Nuclei in differentiated muscle fibres remain post mitotic and do not undergo DNA 
replication except under exceptional circumstances (Iujvidin et al., 1990). In the early stages 
of differentiation the myocytes can be induced to re-enter the cell cycle. These cells can not, 
however, produce contractile proteins (Latham and Konigsberg, 1989). In adults, mitotically 
dormant satellite cells in muscle sarcolemma can be stimulated to enter the cell cycle in 
response to unknown signals induced by muscle damage or exercise (Beauchamp et al., 
2000). These spindle-shaped cells arise from myogenic cells during embryogenesis and 
provide a source of proliferative cells for muscle regeneration either by fusion with injured 
fibres or by forming an entirely new myotube (LaBarge and Blau, 2002).  
 
1.2 Structure of the sarcomere 
 
All striated muscles are built of similar subunits, muscle sarcomeres. These sarcomeres 
are approximately 2-3 µm long and 1-2 µm in diameter and link end to end to form thin 
strands known as myofibrils (Figure 2). Many parallel myofibrils together make up a striated 
muscle fibre, i.e. a single skeletal muscle cell. An adult human muscle fibre is typically 
10-100 µm in diameter and can reach tens of centimetres in length. Bundles of parallel muscle 
fibres make up a striated muscle (Craig and Padron, 2004).  
The striation pattern in muscle, with a sarcomere as one repeat, arises from alternating 
ordered arrays of myofilaments, i.e. myosin and actin filaments (Cooke, 1995). The myosin 
filaments are referred to as thick filaments and actin filaments associated with tropomyosin 
and troponin are referred to as thin filaments (Figure 2). A hexagonal array of aligned, bipolar 
myosin filaments form the central A-band (Anisotropic in polarised light), with adjacent 
filaments being cross-linked at their centres by proteins of the M-band (Mittelscheibe, 
German for `central disc´). Actin overlaps partly with myosin and extends to the Z-disc 
(Zwitter, German for `between´) at both ends of the sarcomere. The actin filaments are polar 
structures, and Z-disc proteins serve to provide a mechanical link between actin arrays of 
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opposite polarity from adjacent sarcomeres. The region of the A-band without any actin-
myosin overlap is called the H-zone (Helle, German for `light´). The regions containing only 
actin filaments are termed I-bands (Isotropic in polarised light). The actin filaments fit into the 
trigonal position of the hexagonal array of myosin filaments in the A-band, but in the I-band 
the lateral organisation of the actin filaments gradually changes to a tetragonal one observed 
at the Z-disc (Squire, 1997) (Figure 2).  
 
 
 
 
 
Figure 2. Striation in skeletal muscle arises from alternating order arrays of myosin and actin 
filaments. Actin filaments in the trigonal position of the hexagonal array of myosin filaments 
(bottom, left). Actin filaments in tetragonal position close to the Z-disc (bottom, right). 
Modified from: 
http://www.emc.maricopa.edu/faculty/farabee/BIOBK/BioBookMUSSKEL.html 
   
= Myosin 
= Actin 
Thin filament 
 
Thick filament  
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The muscle sarcomere is a complex structure. Both thick and thin filaments are 
polymers of non-covalently associated protein molecules. Actin and myosin together account 
for 70% of myofibrillar protein (Hanson and Huxley, 1957; Huxley and Hanson, 1957).  
The myosin filaments are comprised of a two-chain coiled-coil α-helical rod with two 
globular heads at one end. These globular structures can interact with actin and have 
adenosine triphosphatase (ATPase) activity. The rods of concomitant myosin molecules form 
a filament backbone with the heads at the surface. Muscle thin filaments are comprised of 
actin filaments, nebulin and the regulatory proteins tropomyosin and troponin. Nebulin binds 
to actin and the size of nebulin correlates with actin filament length, suggesting that nebulin 
acts as a molecular ruler to determine thin filament length. Both thick and thin filaments are 
connected to titin, believed to be a molecular ruler directing sarcomere assembly (Sanger and 
Sanger, 2001). The regulatory tropomyosin molecules are coiled-coils linked head to tail to 
form long strands that are close to or cover the myosin-binding sites on actin in non-
contracting muscle. Each tropomyosin is associated with one troponin complex, consisting of 
troponin C (binds Ca2+), troponin I (inhibits actin-myosin interaction) and troponin T (binds 
tropomyosin, troponin C and troponin I) (Squire, 1997).  
 
1.3 Function of the sarcomere 
 
Actin and myosin are responsible for the transduction of chemical energy into 
mechanical force in muscle contraction (Hanson and Huxley, 1957; Huxley and Hanson, 
1957). The contraction starts when the action potential triggers the release of Ca2+ from the 
sarcoplasmic reticulum to the muscle fibre. Troponin binds the released Ca2+, shifting the 
position of tropomyosin and changing the structure of the actin monomer (Squire, 1997). The 
outcome is that the myosin-binding sites of actin become exposed enabling the actin-myosin 
interaction. The myosin ATPase is activated by this interaction of the globular head with 
actin. Adenosine triphosphate (ATP) is bound and hydrolysed to adenosine diphosphate 
(ADP) and inorganic phosphate (Pi), which interact with actin. This interaction promotes the 
release of Pi followed by the release of ADP. During this process a structural transition 
postulated to be a change of tilt or shape of the myosin head is believed to produce a sliding 
force between actin and myosin filaments. Myosin heads are released from actin when the 
next ATP molecule binds myosin. In active muscle, many myosin heads undergo ATP-driven 
attachment cycles producing a steady muscle contraction.   
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2    Sarcomeric proteins 
 
Sarcomeres are assembled from thousands of protein subunits into the largest and most 
regular macromolecular complex known. This assembly takes place during the embryonic 
differentiation of heart and skeletal muscle, but also on a continuous basis during the 
physiological turnover of muscle tissue. New sarcomeres are also formed as a result of 
exercise, increased pressure and volume load of the heart, or pathological or hormonal 
stimulation (Young et al., 2001). 
During the myogenesis of mouse skeletal muscle, muscle-specific proteins are 
expressed in a specific order. The first protein to appear when the myotomes begin to 
differentiate at gestation day 9 is desmin. Desmin is followed by titin, muscle-specific actin 
and myosin. Finally nebulin is expressed at gestation day 9.5. At this time fibrous desmin 
structures are already present while the other proteins show no structures. In some myoblasts 
at gestation day 11 and 12, periodic patterns of myosin, nebulin and epitopes of titin located at 
or close to the Z-disc can be observed. After the fusion of myoblasts to myotubes at gestation 
day 14 myotubes show mature myofibril periodicities with all muscle-specific proteins (Furst 
et al., 1989). The expression of myotilin mRNA starts relatively late during muscle cell 
differentation and the protein does not appear at Z-discs until the time of myofibril alignment 
(Salmikangas et al., 2003). 
The process of myofibril assembly requires both spatial and temporal coordination of 
protein interaction with high precision (Gregorio and Antin, 2000). The genomic organisation 
and function of some central molecules (Figure 3) are discussed below.   
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Figure 3. Schematic view of the sarcomere showing the localisation of myosin, thin filament 
proteins, titin and some Z-disc proteins. Modified from Hackman and co-workers (2003). 
 
 
2.1 The thick filament protein myosin 
 
The myosin molecule (530 kDa) is a hexamere consisting of two identical heavy chains 
(233 kDa) and two pairs of light chains (15-22 kDa) (Craig and Knight, 1983). The heavy 
chains are α-helical for their carboxy-terminal half apart from the roughly 20 last residues. 
These α-helices twist around each other, forming a stable double-α-helical coiled-coil tail 155 
nm long (Craig and Knight, 1983; Lowey et al., 1969). The amino-terminal part of each heavy 
chain folds to form a globular head (Rayment et al., 1993). The light chains are of two 
chemically distinct classes, one of each class being associated with each head. The globular  
head of the myosin molecule hydrolyses ATP. The movement in muscle contraction is 
produced through a conformational change in  the myosin heads (Holmes and Geeves, 2000). 
There are altogether 16 genes encoding myosin heavy chains and 9 genes encoding myosin 
light chains. Different myosin isoforms are expressed in different muscles and non-muscle 
tissues and in muscles of different developmental stages (http://www.gene.ucl.ac.uk/cgi-
bin/nomenclature/searchgenes.pl). The speed of the contraction of a muscle fibre is dependent  
on the ATP activity of its myosin. The type of fibre correlates with the myosin heavy-chain 
(MyHC) isoform it expresses; slow type I fibres contain type I, slow MyHC, while fast types 
α-actinin
titin 
capZ 
myotilin 
actin 
nebulin tropomyosin/ 
troponin myosin 
telethonin 
Sarcomere 
A Band I Band I Band 
H Zone 
tropomodulin     
myopalladin    
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IIa and IIb express types IIa and IIb, fast MyHC, respectively. In humans, primary myotubes 
express only embryonic, perinatal and/or slow MyHC (Rubinstein and Kelley, 2004).      
 
2.2 Thin filament proteins 
2.2.1 Actin 
 
The actin monomer (G-actin) (42 kDa) is a globular protein consisting of a single 
polypeptide chain with 375 amino acid residues. One-quarter of the residues are arranged in 
an α-helical fold and one-quarter are in a β-helical fold, the rest are randomly coiled (Kabsch 
and Vandekerckhove, 1992). Actin is encoded by at least six different genes 
(http://www.ncbi.nlm.nih.gov/genome/guide/human/), giving rise to skeletal muscle, cardiac 
muscle, smooth muscle and non-muscle isoforms. In skeletal and cardiac muscle, α-actin is 
the backbone of the thin filament. ACTA1 encoding skeletal muscle α-actin is located on 
chromosome 1q42. The gene is comprised of six coding exons encoding a 1374 base pairs 
(bp) long transcript (Nowak et al., 1999). The amino acid sequences of the different actin 
isoforms are highly conserved (Herman, 1993; Khaitlina, 2001). Actin interacts with over 160 
proteins (dos Remedios et al., 2003) (including α-actinin, tropomyosin, troponin, myosin and 
nebulin) and the binding sites for these molecules need to be conserved, explaining the overall 
homology between diverse actins (Kabsch et al., 1990). The actin monomer is roughly 
spherical with a diameter of approximately 5.5 nm consisting of two major domains of similar 
size. Each domain can be divided into subdomains. A molecule of ATP or ADP is located in a 
cleft between the domains with a Ca2+ or Mg2+ ion bound to the phosphate (Holmes and 
Kabsch, 1991; Kabsch et al., 1990; Kabsch and Vandekerckhove, 1992). At low ionic strength 
actin exists in the monomeric G-actin form, and when the ionic strength is increased actin 
self-associates to form filamentous actin (F-actin). This polymerisation is accompanied by 
hydrolysis of bound ATP to ADP. F-actin filaments are composed of two strands of actin 
subunits twisted around each other to form a right-handed double helix with 13-14 subunits 
per turn (Depue and Rice, 1965; Hanson, 1967; Huxley and Brown, 1967; O'Brien and 
Dickens, 1983). F-actin has a polar structure, with all monomers pointing in the same 
direction along the filament axis (Huxley, 1963; Moore et al., 1970). Actin filaments 
functioning in intracellular transport and cell motility activities are critically dependent on 
their ability to polymerise and depolymerise as needed. Polymerisation occurs preferentially 
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at the fast-growing barbed end of the filament which in striated muscle is located at the 
Z-disc. Depolarisation occurs more rapidly and polarisation more slowly at the slow-growing 
pointed end of the filament, corresponding to the end that in striated muscle is at the M-line 
(Cooper and Schafer, 2000).      
 
2.2.2 Nebulin and nebulette 
 
Nebulin is a giant (600-900 kDa) muscle protein expressed predominantly in the thin 
filaments of skeletal muscle. The gene encoding human nebulin (NEB) is located on 
chromosome 2q21.2-q22 (Pelin et al., 1997). Nebulin binds to actin and the size of nebulin 
correlates with actin filament length, suggesting that nebulin may determine the length of the 
thin filaments during myofibrillogenesis. Most (97%) of the nebulin polypeptide consists of 
modules 30-35 amino acid residues long, arranged into simple repeats. In the central part of 
the molecule these repeats are arranged into super repeats, each consisting of seven simple 
repeats. In addition to conserved actin-binding motifs consisting of serine, and typically 
aspartic acid, tyrosine and lysine or arginine (SDXXYK, X = variable amino acid) located at 
each repeat module, conserved motifs consisting of tryptophan, leucine, lysine or arginine, 
isoleucine and glycine (WLKGIGW) have been identified at intervals corresponding to the 
length of one super repeat. These motifs likely bind the troponin-tropomyosin complex. Both 
the 8 kDa amino-terminal and the 20 kDa carboxy-terminal ends contain unique protein 
domains. The carboxy-terminus contains a serine-rich domain with potential phosphorylation 
sites and a conserved src (tyrosine kinase) homology 3 (SH3) domain. This part of the 
molecule is anchored in the Z-disc of the muscle sarcomere (Labeit and Kolmerer, 1995a; 
Pfuhl et al., 1996). There is evidence that the SH3 domain might bind titin (Politou et al., 
2002). Myopalladin links nebulin to α-actinin in the Z-discs (Bang et al., 2001b) and the Z-
disc peripheral region of nebulin has been shown to bind desmin (Bang et al., 2002). The 
three extreme amino-terminal simple repeats of nebulin located at or near the pointed end of 
the thin filament bind tropomodulin, a protein that together with nebulin probably determines 
thin filament length (McElhinny et al., 2001). 
Nebulette (109 kDa), is a nebulin-like protein expressed only in cardiac muscle 
(Millevoi et al., 1998). The predicted protein structure is similar to nebulin, consisting of 
modular repeat structures of 35 amino acid residues. Its domain architecture is highly similar 
to that of the carboxy-terminal one-third 100 kDa of nebulin (Labeit and Kolmerer, 1995a). In 
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addition, nebulette binds to actin and plays an important role in the assembly of the Z-disc 
(Moncman and Wang, 1999). The nebulette gene, NEBL, located on chromosome 10p12 
(Millevoi et al., 1998) includes 28 exons with the translation initiation codon in the first exon 
and the stop codon in the last exon encoding the SH3 domain. There are two regions with 
alternatively spliced exons in this gene (Arimura et al., 2000; Millevoi et al., 1998).    
 
2.2.3 Tropomyosins 
 
Tropomyosins (65 kDa) are a family of actin-filament-binding proteins expressed in 
most eukaryotic cells. In vertebrates different isoforms are expressed in skeletal muscle, 
cardiac muscle, smooth muscle and non-muscle cells. These isoforms are encoded by at least 
four different genes all located on different chromosomes (Lin et al., 1997; McAlpine et al., 
1993; Pittenger et al., 1994). Fast α-tropomyosin, expressed principally in cardiac muscle and 
in fast, skeletal muscle is encoded by TPM1 located on chromosome 15. β-Tropomyosin 
accounts for 65% of the tropomyosin expressed in slow muscle fibres, whereas fast muscle 
fibres express 29% β-tropomyosin (Pieples and Wieczorek, 2000). It is expressed 
predominantly in skeletal muscle and is encoded by TPM2 located on chromosome 9p13.2-
p13.1. TPM3, located on chromosome 1q22-23, predominantly encodes skeletal muscle slow 
γ-tropomyosin. The TPM4 gene, located on chromosome 19 (McAlpine et al., 1993), encodes 
non-muscle tropomyosin (Pittenger et al., 1994). The amino acid sequences of the different 
tropomyosin isoforms are conserved.   
The muscle-specific isoforms of different tropomyosin genes are differentially 
expressed in different muscle fibre types and in cardiac muscle. Further diversity is generated 
by alternative splicing and alternative promoter usage (Durling et al., 2002; Gunning et al., 
1990). Regions that differ between isoforms appear to encode functional domains involved in 
head-to-tail binding and coiled-coil interactions of the tropomyosin molecules and their 
binding to actin, caldesmon, tropomodulin and troponin-T (Lin et al., 1997; Pittenger et al., 
1994). The mRNA transcripts encoded by 10-11 exons of tropomyosin genes range between 
1000 and 1200 bp in length (Lees-Miller and Helfman, 1991).   
Tropomyosin molecules, coiled-coil dimers of 284 amino acid residue α-helices, 
associate with each strand of the actin helix in such a manner that each coiled-coil binds to 
seven actin monomers, as well as with neighbouring tropomyosins. Neighbouring 
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tropomyosins bind to each other through head-to-tail contacts forming continuous extended 
polymers overlapping each other by approximately 2 nm.  
Associated with each tropomyosin is a troponin complex that makes contact along the 
carboxy-terminal third of the coiled-coil including the head-to-tail overlap region (Ohtsuki et 
al., 1986; Zot and Potter, 1987).  The function of tropomyosins in skeletal and cardiac muscle 
is, in conjunction with the troponin complex, to regulate the calcium-sensitive interaction of 
actin and myosin during muscle contraction (Ebashi et al., 1969; Farah and Reinach, 1995; 
Greene and Eisenberg, 1980). Regions that differ between isoforms appear to encode 
functional domains involved in head-to-tail binding and coiled-coil interactions of the 
tropomyosin molecules and their binding to actin, caldesmon, tropomodulin and troponin-T 
(Lin et al., 1997; Pittenger et al., 1994).      
 
2.2.4 Troponin 
 
Troponin (80 kDa) is a complex of three non-covalently linked subunits, troponin I 
(TnI), troponin T (TnT) and troponin C (TnC), named according to their first identified 
functions. Troponin and tropomyosin form a Ca2+-sensitive complex which regulates the 
interaction between actin and myosin (Farah and Reinach, 1995; Gordon et al., 2000; Solaro 
and Rarick, 1998).  
TnI is a basic, globular protein containing approximately 180 amino acids. When bound 
to F-actin TnI inhibits actin-myosin ATPase. The inhibitory function is greatly enhanced in 
the presence of tropomyosin. TnI binds actin and is the subunit that holds the troponin 
complex together (Gordon et al., 2000).  
TnC is the Ca2+-binding component of troponin (Gordon et al., 2000). It is a 
dumbbell-shaped protein with two globular domains connected by a long central helix 
(Satyshur et al., 1988). There are a number of isoforms of TnC specific to particular muscle 
types or muscles at different developmental stages (Kretsinger, 1980). TnC can bind TnI and 
TnT and possibly also actin. In the presence of Ca2+ TnC removes the inhibition of the 
actin-myosin interaction that TnI imposes on the thin filament. When the Ca2+ concentration 
decreases the amount of Ca2+ bound to TnC is diminished and the filaments revert to the 
inhibited state.  
TnT is the rod-shaped tropomyosin-binding component of troponin (Gordon et al., 
2000; Perry, 1998). The occurrence of TnT in a wide variety of isoforms enables fine tuning 
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of the contractile regulation. TnT is an extended molecule with its globular carboxy-terminus 
interacting with TnC, TnI and tropomyosin, while its extended amino-terminal region lies 
alongside and antiparallel to the carboxy-terminal part of tropomyosin.  
The genes encoding TnI and TnT are organised as paralogous pairs at three dispersed 
chromosomal sites, each containing a TnI-TnT gene pair (Barton et al., 1997). The TNNI1 and 
the TNNT2 genes are located on chromosome 1q32. TNNI2 and TNNT3 are located on 
chromosome 11p15.5 and TNNI3 and TNNT1 located on chromosome 19q13.4. The 
organisation of these genes suggests that they were derived by duplication of a single locus 
containing an ancestral TnI-TnT gene pair. TNNI1 and TNNT1  encode TnI and TnT isoforms 
expressed in slow skeletal muscle. TNNI2 and TNNT3 encode fast muscle isoforms of TnI and 
TnT while TNNI3 and TNNT2 encode isoforms expressed in cardiac muscle (Barton et al., 
1999).  
In contrast to these genes, the genes encoding fast skeletal muscle TnC and cardiac/slow 
skeletal muscle TnC are not linked to each other or to other troponin genes (Townsend et al., 
1997a; Townsend et al., 1997b). TNNC1, the gene for cardiac/slow skeletal muscle TnC, is 
located on chromosome 3p14.3-21.3 while TNNC2, encoding fast skeletal muscle TnC, is 
situated on chromosome 20q12-13.11 (Barton et al., 1999; Townsend et al., 1997a; Townsend 
et al., 1997b). Human troponin genes have 6-15 exons. All troponin T genes and TNNT1 are 
alternatively spliced (http://www.gene.ucl.ac.uk/cgi-bin/nomenclature/searchgenes.pl). 
 
2.2.5 Tropomodulin and CapZ 
 
Actin filaments in striated muscles are relatively stable and have a precise lengths. The 
length of the filaments are controlled by tropomodulin, which regulates the slow-growing 
(pointed) end of actin filaments, and CapZ which regulates the fast-growing (barbed) end. 
Tropomodulin (43 kDa) is a thin-filament pointed-end capping protein that together 
with nebulin likely determines actin filament length in the muscle sarcomere. When bound to 
the thin-filament pointed end tropomodulin stabilises the filament by preventing actin 
polymerisation and depolymerisation (McElhinny et al., 2001). The carboxy-terminal part of 
tropomodulin binds specifically to actin concurrently with the amino-terminal part binding to 
tropomyosin. The capping activity is dependent on the interaction between tropomodulin and 
tropomyosin, and the absence of tropomyosin greatly reduces the tropomodulin capping 
activity (Weber et al., 1994). Tropomodulin binds the amino-terminal part of nebulin 
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(McElhinny et al., 2001). In humans there are at least three genes encoding tropomodulin. 
These are TMOD2 encoding tropomodulin 2 expressed in the nervous system, TMOD3 
encoding tropomodulin 3 with a ubiquitous expression pattern and TMOD4 encoding muscle-
specific tropomodulin 4. TMOD2 and TMOD3 are located close to each other on chromosome 
15q21.1-q21.2. TMOD4 is on chromosome 1q12. TMOD4 encodes at least two different 
tropomodulin 4 isoforms; erythrocyte tropomodulin expressed in slow skeletal muscle, in 
embryonic skeletal muscle and in the heart, and skeletal tropomodulin (Sk-Tmod) expressed 
late in differentiation in fast skeletal muscle (Cox and Zoghbi, 2000; McElhinny et al., 2001).  
CapZ is a heterodimer composed of a 36 kDa α-subunit and a 32 kDa β-subunit (Casella 
et al., 1986). It associates with high affinity to the barbed ends of actin filaments inhibiting 
actin monomer association and dissociation at the Z-disc (Stossel et al., 1985). During 
myofibril formation CapZ is incorporated into nascent Z bodies before mature actin striation 
occurs, showing the importance of this protein in regulation of thin filament assembly. 
Inhibition of CapZ during myofibrillogenesis causes a delay in the organisation of actin in the 
I-bands (Schafer et al., 1995). CapZ is encoded by four different genes; CAPZA1, CAPZA2, 
CAPZA3 and CAPZB located on chromosomes 1p13.2, 7q31.2-q31.3, 12p12.3 and 1p36.1, 
respectively. All these genes encode proteins which are expressed in the muscle Z-disc. In 
addition, there is a CAPZ pseudogene located on the X chromosome.  
 
2.3 Titin 
 
Titin (700-3700 kDa), also known as connectin, was first described by Maruyama and 
co-workers in 1977. It is the only known structure that spans the entire half-sarcomere 
(Maruyama et al., 1977). It has been suggested to have a function as a third set of myofibrillar 
filaments in addition to thick and thin filaments (dos Remedios and Gilmour, 1978). The 
complete titin polypeptide is formed by a single strand of 27,000-34,000 residues (Labeit and 
Kolmerer, 1995b). It acts as a molecular blueprint for sarcomere assembly, providing specific 
attachment sites for other sarcomeric proteins by determining their precise position in the 
muscle sarcomere (Sanger and Sanger, 2001; Tskhovrebova and Trinick, 2003). Through its 
elastic properties it acts as a molecular spring (Tskhovrebova and Trinick, 2003). 
Additionally, the kinase domain of titin has recently been shown to have regulatory properties 
controlling muscle gene expression and protein turnover (Lange et al., 2005). This giant 
molecule is the third most abundant protein in the muscles. It is composed of 132 copies of 
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100-residue repeats belonging to the fibronectin type III (FNIII) superfamily and up to 166 
copies of 90-95 residues of immunoglobulin (Ig)-like repeats. Together the Ig and FNIII 
repeats account for 90% of the molecule’s mass (Gregorio et al., 1999). The amino-terminal 
80 kDa (or less, depending on the isoform) spans the entire Z-disc region with titin filaments 
from opposite sarcomeres overlapping within the Z-disc. There are at least four potential 
binding sites for α-actinin within this region of the molecule (Gregorio et al., 1998). 
Depending on the isoform, between 800 kDa and 1.5 mega-Dalton (MDa) of titin is located 
within the I-band. The central elastic section of  I-band titin is formed by tandemly arranged 
Ig repeats contained in two separate blocks (Witt et al., 1998). The carboxy-terminal 2 MDa is 
located in the A-band in tight association with the myosin thick filament (Labeit and 
Kolmerer, 1995b). The M-line region of titin corresponds to appoximately 200 kDa of the 
final carboxy-terminal region of the protein. This part of the molecule has a kinase domain 
(Obermann et al., 1996). Titin filaments from opposite half-sarcomeres overlap in the M-line 
in the same manner as they do in the Z-disc (Gregorio et al., 1998). The titin gene (TTN), 
located on chromosome 2q31, is comprised of 363 exons spanning 294 kilobase pairs (kb) of 
genomic sequence (Bang et al., 2001a). Alternatively spliced exons encode those parts of titin 
that are located in the Z-disc (Gregorio et al., 1998), the I-band (Witt et al., 1998) and the M-
line (Kolmerer et al., 1996).    
 
2.4 Z-disc proteins 
2.4.1 α-Actinin  
 
α-Actinins (100 kDa) are members of the spectrin protein superfamily. They consist of 
an amino-terminal actin-binding domain, a central rod composed of four spectrin-like repeats, 
and a carboxy-terminal domain with a pair of helix-loop-helix Ca2+-binding motifs called EF 
hands (Otey and Carpen, 2004). There are four α-actinin genes in humans; ACTN2 and 
ACTN3 encoding sarcomeric α-actinin, ACTN4 encoding smooth muscle and non-muscle 
α-actinin and ACTN1 encoding non-muscle α-actinin. All α-actinin genes share extensive 
homology and have similar molecular weights. The α-actinin 2 protein encoded by ACTN2 is 
organised as an anti-parallel dimer and localises at the Z-discs, where it anchors actin 
filaments (Tiso et al., 1999). α-Actinin 2 binds multiple Z-disc proteins, including ZASP 
(Faulkner et al., 1999), myozenin 1 (Faulkner et al., 2000) and myopalladin (Bang et al., 
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2001b). It also possesses a titin- (Sorimachi et al., 1997) and a myotilin- (Salmikangas et al., 
1999) binding site and is able to bind the C-terminus of dystrophin (Hance et al., 1999). 
α-Actinin 2 is co-expressed with α-actinin 3 in skeletal muscle but in cardiac muscle only 
α-actinin 2 is expressed (Beggs et al., 1992). The ACTN2 gene is on chromosome 1q42-q43 
and the ACTN3 gene is on chromosome 11q13-q14. Both genes have 21 exons spanning 40 kb 
of genomic sequence (Tiso et al., 1999). ACTN3 is expressed in a subset of fast fibres only, 
and is not required for normal muscle function (Yang et al., 2003).   
 
2.4.2 Myopalladin 
 
Myopalladin (145 kDa) is a sarcomeric protein with multiple roles in Z-disc and I-band 
protein assemblies. Together with palladin and myotilin, myopalladin forms a novel gene 
family. The carboxy-terminal part harbours a binding site for the nebulin SH3 domain and a 
binding site for the EF hand motif of α-actinin. It is predicted that myopalladin and α-actinin 
may form a linking system, tethering the barbed ends of actin thin filaments, the 
amino-terminal ends of titin filaments and the carboxy-terminal ends of nebulin filaments 
within the Z-disc. The amino-terminal region specifically binds to the cardiac ankyrin repeat 
protein (CARP) (Bang et al., 2001b), a nuclear protein involved in the control of muscle gene 
expression (Zou et al., 1997). The myopalladin gene, MYPN is on chromosome 10q22.1. The 
myopalladin gene encodes a protein 1320 amino acids long http://www.gene.ucl.ac.uk/cgi-
bin/nomenclature/searchgenes.pl. Its expression is restricted to heart and skeletal muscle 
(Bang et al., 2001b). 
 
2.4.3 Myotilin (myofibrillar protein with titin-like Ig domains) 
 
Myotilin (57 kDa) is expressed in skeletal and heart muscle. It binds actin in a 1:1 ratio 
and cross-links actin filaments into large, stable bundles both in vivo and in vitro. 
Furthermore, myotilin stabilises the assembled actin bundles, probably by decreasing the off-
rate of actin monomers from filament ends (Salmikangas et al., 2003). It co-localises with and 
directly binds to α-actinin in the sarcomeric Z-discs. Myotilin also localises along the 
sarcolemmal membrane. The amino-terminal sequence is unique while the carboxy-terminal 
half of the protein contains two Ig-like domains that are homologous to palladin, myopalladin 
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and titin Ig domains. The myotilin Ig domains are important for actin binding and are required 
for the formation of antiparallel myotilin dimers (Salmikangas et al., 2003; von Nandelstadh 
et al., in press). The homology between the Ig domains of titin and myotilin suggests a shared 
sequence motif for subcellular localisation (Salmikangas et al., 1999). The human myotilin 
gene, TTID, maps to chromosome 5q31 and the 498 amino acid residue protein transcript is 
encoded by 10 exons (Hauser et al., 2000). 
 
2.4.4 Desmin 
 
Desmin (52 kDa) is an intermediate filament (IF) protein of muscle and endothelial cells 
(Ishikawa et al., 1968). Several molecules have been reported to associate with desmin. 
Among these are the other IF proteins, the gene regulatory protein MyoD, (Costa et al., 2004) 
and nebulin (Bang et al., 2002), probably linking desmin to the  Z-disc (Bang et al., 2002). 
Desmin is encoded by a single 9-exon gene, DES, in all vertebrates. The human gene is on 
chromosome 2q35. The protein, comprised of 470 amino acids, consists of two conserved 
central rod domains, four linker regions and two variable globular end domains. Although the 
precise structure of the filament is unclear, it is known that IF molecules associate laterally in 
pairs and these in turn associate with each other. The central rod domain of desmin is 
responsible for polymerisation by lateral association (Herrmann and Aebi, 2000). Desmin is 
expressed from the early formation of skeletal, cardiac and smooth muscles and endothelial 
cells. In mouse embryos fibrous desmin structures can be observed as early as gestation day 
9.5 (Furst et al., 1989). In skeletal muscle desmin is concentrated at the Z-disc, around the 
nucleus and in the costameres, although the molecule can be observed all across the cell 
(Ervasti, 2003). In cardiac and smooth muscles the cellular distribution of desmin differs 
somewhat from that in skeletal muscle (Stromer and Bendayan, 1988; Tokuyasu et al., 1983). 
Since the identification of desmin, it has been attributed many functions. The ability of the 
molecule to bind DNA and its cellular distribution suggest a role in the regulation of gene 
expression (Hutchison, 2002; Tolstonog et al., 2002). Desmin knock-out mice have displaced 
mitochondria, suggesting a function in mitochondrial localisation (Milner et al., 2000). 
Desmin has also been suggested to be responsible for the elastic properties of muscle (Shah et 
al., 2004).    
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2.4.5 Other Z-disc associated proteins 
 
ZASP (Z-disc alternatively spliced PDZ-motif) (32–78 kDa) is a Z-disc protein 
expressed in human cardiac and skeletal muscle (Faulkner et al., 1999). The amino-terminal 
PDZ domain, believed to be involved in the direction of intracellular proteins to multiprotein 
complexes, interacts with the carboxy-terminus of α-actinin 2, probably by forming a ternary 
complex with titin Z repeats (Au et al., 2004). The human ZASP gene, LDB3, is located on 
chromosome 10q22.3-q23.2 and consists of 13 exons. At least two different sized proteins 
have been detected in both cardiac and skeletal muscle, suggesting that the gene is 
alternatively spliced (Faulkner et al., 1999).  
Myozenin 1 (also known as FATZ and calcarcin) (32 kDa) is an γ-filamin-, α-actinin- 
and telethonin-binding protein expressed predominantly in skeletal muscle (Takada et al., 
2001). It has been found to function as a linker protein connecting calcineurin, an important 
calcium-dependent protein phosphatase, to the Z-disc and is probably is not primarily 
involved in the Z-disc structure (Frey et al., 2000). The myozenin 1 gene, MYOZ1, includes 
six exons and is located on chromosome 10q22.1-q22.2 (Takada et al., 2001). There are two 
additional myozenin genes, MYOZ2 encoding myozenin 2 expressed in cardiac and skeletal 
muscle (Ahmad et al., 2000) and MYOZ3 encoding myozenin 3 expressed in the skeletal 
muscle (Frey and Olson, 2002)  
γ-Filamin (also known as ABP-L) (291 kDa) is a filamin isoform predominantly 
expressed in striated muscle Z-discs (Thompson et al., 2000). Filamins (α-filamin, β-filamin 
and γ-filamin encoded by FLNA, FLNB and FLNC, respectively) are rod-shaped molecules 
with an actin-binding amino-terminal domain and 24 Ig domains. Different isoforms are 
expressed differentially in various cell types. γ-Filamin differs from the other filamins in that 
it contains a unique insertion in the middle of Ig-domain 20 (Fucini et al., 1997; Gorlin et al., 
1990). This domain is sufficient for targeting the isoform to Z-discs of cardiac and skeletal 
muscle cells. It has been shown to bind myotilin and it has been implicated that γ-filamin 
might be indirectly anchored to α-actinin in the Z-disc via myotilin (van der Ven et al., 2000). 
The γ-filamin gene, FLNC, includes 48 exons and is located on chromosome 7q32-q35 
(Gariboldi et al., 1994).   
Telethonin (19 kDa) (also known as T-cap) is expressed in cardiac and skeletal muscle 
(Valle et al., 1997). It functions as a flexible adaptor protein that links signaling and structural 
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proteins to titin at the Z-disc (Granzier and Labeit, 2004). The telethonin gene, TCAP, has two 
exons and is located on chromosome 17q12 (Valle et al., 1997).   
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3 Nemaline myopathy  
 
Nemaline myopathy (NM) is a rare, and both clinically and genetically heterogeneous 
muscle disorder defined on the basis of ultrastructural abnormalities, i.e. nemaline bodies, in 
the muscle fibres. The nemaline bodies consist of actin filament aggregates and Z-disc 
associated material including α-actinin 2 (Jockusch et al., 1980; Wallgren-Pettersson et al., 1995) 
and myotilin (Schroder et al., 2003). Nebulin and desmin have also been reported as components 
of nemaline bodies (Gurgel-Giannetti et al., 2001; Jockusch et al., 1980). The common clinical 
features of all nemaline myopathies are muscle weakness and hypotonia (Figure 4) (Conen et 
al., 1963; Shy et al., 1963). Inheritance in the majority of familial cases is autosomal recessive 
(Johnston et al., 2000; Nowak et al., 1999; Pelin et al., 1999; Tan et al., 1999), although some 
families have been described with an autosomal dominant mode of inheritance (Durling et al., 
2002; Ilkovski et al., 2001; Laing et al., 1995; Nowak et al., 1999). The disease spectrum 
forms a continuum, from prenatal, very severe forms through the typical congenital, usually 
slowly progressive form to forms with later onset (Wallgren-Pettersson and Laing, 2000; 
Wallgren-Pettersson et al., 1999).  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4. NM is a clinically heterogeneous disorder varying from severe congenital forms 
(left) to milder forms (right). Modified from Wallgren-Pettersson and co-workers (2002) and 
Wallgren-Pettersson and co-workers (2004). 
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3.1 Clinical features and classification 
 
NM has been subdivided into six different clinical categories. These are severe 
congenital NM, intermediate congenital NM, typical congenital NM, mild childhood or 
juvenile onset NM, adult onset NM and other forms (Wallgren-Pettersson and Laing, 2000; 
Wallgren-Pettersson et al., 1999). The categories have been outlined using the typical form as 
a starting-point and the other categories have then been defined on the basis of different ages 
of onset or grades of severity or progression, or because of unusual associated features 
(Wallgren-Pettersson and Laing, 2000). A clinical classification permitting accurate 
prognosication or the determination of the mode of inheritance, however, awaits further 
molecular genetic studies and genotype-phenotype correlations. A few correlations can 
nevertheless be discerned at this time; in patients with nebulin mutations, the typical form of 
NM predominates, while severe NM is the most common form in patients with α-actin 
mutations. In families showing an autosomal recessive inheritance pattern, nebulin mutations 
are the most common cause, while families with an autosomal dominant mode of inheritance 
are likely to segregate an actin mutation (Wallgren-Pettersson et al., 2004b).  
 
3.1.1 Severe congenital NM 
 
Severe congenital NM constitutes a category of patients who at birth have one or more 
of the following clinical features: absence of spontaneous movement, absence of spontaneous 
respiration or the presence of contractures or fractures (Wallgren-Pettersson and Laing, 2000; 
Wallgren-Pettersson et al., 1999). The prognosis for these patients is often poor (Wallgren-
Pettersson et al., 1999).  
 
3.1.2 Intermediate congenital NM 
 
Intermediate congenital NM is similar to the typical form in infancy, but later has a 
more severe course. These patient are breathing and moving at birth, but later in early 
childhood either become permanently ventilator-dependent or are unable to achieve sitting or 
walking, develop contractures or require wheelchairs before the pre-pubertal period of rapid 
growth (Wallgren-Pettersson and Laing, 2000).  
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3.1.3 Typical congenital NM    
 
The onset of typical congenital NM is usually, as the name implies, congenital, but the 
age at diagnosis ranges from infantile (Wallgren-Pettersson et al., 1999) to early childhood 
(Wallgren-Pettersson and Laing, 2000). The infants are often floppy at birth, with feeding 
difficulties and insufficient respiration. Muscle weakness is generalised but especially 
pronounced in the facial, bulbar and respiratory muscles, and in the neck flexors. The facies is 
myopathic and the gait is waddling. Scoliosis is common with onset usually in the pre-
pubertal period of rapid growth. The weakness of the limbs is initially proximal and later also 
distal, with a slowly progressive or non-progressive course. The dorsiflexors of the feet are 
especially severely affected, particularly in patients with mutations in NEB (Jungbluth et al., 
2004; Wallgren-Pettersson et al., 2004b). Affected children usually survive infancy if actively 
treated and achieve motor milestones, albeit later than unaffected children. Chief clinical 
concerns are swallowing difficulties with associated risk of aspiration, the possible 
development of scoliosis, and in particular the risk of deterioration of respiratory function 
even in ambulant patients (Wallgren-Pettersson et al., 2004a). Many patients remain ambulant 
as adults (Wallgren-Pettersson and Laing, 2000; Wallgren-Pettersson et al., 1999).    
 
3.1.4 Mild childhood or juvenile onset NM 
 
The symptoms of mild childhood or juvenile onset NM begin at pre-school or school 
age. These patients may have no facial weakness, no cardiomyopathy, nor do they have foot 
drop (Wallgren-Pettersson and Laing, 2000). 
   
3.1.5 Adult onset NM 
 
The clinical picture of this form of NM is variable, with the only common feature being 
the adult onset of the disease (Wallgren-Pettersson and Laing, 2000). Some of the cases 
classified into this category probably have other than genetic etiology. 
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3.1.6 Other forms of NM 
 
Patients with unusual associated features have been classified as a separate group. 
Patients with this form of NM have, in addition to fulfilling the basic criteria, either 
cardiomyopathy, ophthalmoplegia, an unusual distribution of muscle weakness or intranuclear 
nemaline bodies. These features are exclusion criteria for all other categories of NM 
(Wallgren-Pettersson and Laing, 2000).  
A distinctive form of NM, also called Amish nemaline myopathy (ANM), belonging to 
this category has been identified among the Old Order Amish. In the first months of life, 
affected infants have tremor, hypotonia and mild contractures of the shoulders and hips. 
Progressive worsening of the proximal contractures, weakness, and a pectus carinatum 
deformity develop before the children die of respiratory insufficiency, usually during the 
second year of life (Johnston et al., 2000). ANM differs from severe congenital NM 
(Wallgren-Pettersson and Laing, 2000; Wallgren-Pettersson et al., 1999) in that all neonates 
have tremor evident at birth and involving most skeletal muscle groups. They also have 
progressive worsening of the weakness and the proximal contractures. ANM has an incidence 
of  1 in 500 among the Old Order Amish (Johnston et al., 2000).  
 Another distinct form belonging to this category has been identified in a large 
Australian family with disease onset at school age. In this family the weakness develops in the 
distal parts of the lower limbs while the upper limbs are initially unaffected or less severely 
affected. The weakness is slowly progressive and finally affects all ankle muscles and all 
muscles of the upper limbs (Laing et al., 1992; Laing et al., 1995). 
         
3.2 Histological findings     
 
The histological hallmark of NM is the formation of nemaline bodies or rods (Figure 5). 
The characteristic light microscopic findings in a muscle biopsy section stained with the 
Gomori trichrome method are dark red or purple nemaline body clusters under the 
sarcolemma or around the nuclei (Conen et al., 1963; Shy et al., 1963). Predominance of slow 
type I fibres is a common feature in muscle biopsies, as is a difference in fibre size between 
type I and type II fibres, in many cases fulfilling the criteria for congenital fibre type 
disproportion (Wallgren-Pettersson et al., 1988). The nemaline bodies are highly ordered 
structures. When viewed under the electron microscope, they appear to originate from the 
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Z-disc and show a filamentary structure with double striation. In transverse section, filaments 
in rods form a tetragonal array resembling the lattice of a normal Z-disc (Engel and Gomez, 
1967).  
 
 
    
 
 
 
 
 
 
    
 
 
Figure 5. Modified Gomori trichrome-stained longitudinal section labelled with antibodies 
 
 
The nemaline bodies appear to be extensions of Z-discs, and in fact consist of actin, 
α-actinin and other Z-disc proteins (Schroder et al., 2003; Wallgren-Pettersson et al., 1995). 
The quantity of nemaline bodies varies greatly in different muscles and even in different parts 
of the same muscle (Karpati et al., 1971; Nienhuis et al., 1967). Occasionally a second biopsy 
is needed to verify the presence of nemaline bodies, confirming the diagnosis of NM  
(Wallgren-Pettersson et al., 1990). Intranuclear bodies are rare and often associated with 
severe NM (Wallgren-Pettersson et al., 2004b). 
Some similar sarcomeric accumulations are also seen in two other inherited disorders. 
These are myofibrillar myopathy (MFM) and central core disease (CCD). The histological 
hallmarks of MFM are variability in fibre size, myofibrillar disruption and intrafibre 
aggregates that contain beta-amyloid and immunostain for desmin and/or myosin and myotilin 
(Horowitz and Schmalbruch, 1994; Selcen et al., 2004) and multiple other proteins (Carlsson 
and Thornell, 2001; Goldfarb et al., 2004). Typical features of the lesions in CCD are variable 
degrees of myofibrillar disorganisation, abnormal accumulation of Z-disc proteins and 
from Wallgren-Pettersson and co-workers (1995).   
against -actinin. Nemaline bodies are indicated with arrows. Magnified x 500 Modified α
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absence of mitochondria and sarcoplasmic reticulum (Monnier et al., 2001). Like nemaline 
bodies, cores can be labelled with antibodies against myotilin (Schroder et al., 2003). 
Although immunolabelling of nemaline bodies demonstrates the presence of the same 
sarcomeric proteins as those observed in MFM the labelling of the rods is more discrete. In 
CCD, the structure of the core lesions is usually clearly distinct from nemaline bodies. 
Staining with the Gomori trichrome method clearly distinguishes red-staining rods and often 
highlights the absence of mitochondria in core lesions (Caroline Sewry, personal 
communication).   
Nemaline bodies have not been found in smooth (Matsuo et al., 1982) or cardiac muscle 
(Karpati et al., 1971; McMenamin et al., 1984; Shafiq et al., 1967) in patients with NM. 
Nemaline bodies are relatively non-specific features and are sometimes associated with HIV 
infection (Simpson and Bender, 1988), haemodialysis (Savica et al., 1983), and acute 
schizophrenia (Melzer et al., 1973). They have also been induced experimentally in rat muscle 
by tenotomy (Karpati et al., 1972; Sharfiq et al., 1969). Nemaline bodies also occur normally 
in extraocular muscles (Martinez et al., 1980), myotendinous junctions (Mair and Tome, 
1972) and in the muscles of aged persons (Tomonaga, 1977).   
   
3.3 Genes underlying NM 
 
NM is genetically heterogeneous. Prior to this study, mutations in four different genes 
had been associated with NM. These are: slow γ-tropomyosin (TPM3) (Durling et al., 2002; 
Laing et al., 1995; Tan et al., 1999; Wattanasirichaigoon et al., 2002), nebulin (NEB) (Pelin et 
al., 1999), skeletal muscle α-actin (ACTA1) (Ilkovski et al., 2001; Nowak et al., 1999) and 
slow troponin T (TNNT1) (Johnston et al., 2000). These are all genes encoding thin filament 
proteins of the muscle sarcomere. However, there are additional families with NM that do not 
show linkage to any of the identified loci, suggesting further genetic heterogeneity (Wallgren-
Pettersson et al., 1999). Mutations in NEB and ACTA1 seem to be the main causes of NM, as 
most of the pathogenic mutations have been reported in these genes. The marked variability in 
clinical phenotype among patients with mutations in NEB and ACTA1 suggests that both the 
site of the mutation, the nature of the amino acid change and in nebulin the site of the 
frameshift have differential effects on thin filament formation and protein-protein interactions.       
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3.3.1 The γ-tropomyosin gene, TPM3  
 
Positional cloning (Laing et al., 1992) and reassignment of the γ-tropomyosin gene, 
TPM3, to the linked region (Wilton et al., 1995) led to identification of the first mutation ever 
recognised as causing NM. This was a missense mutation in exon 1 of TPM3 identified in a 
large Australian pedigree (Laing et al., 1995). Mutations in this gene are, however, rare, with 
mutations identified to date, in four families only (Durling et al., 2002; Laing et al., 1995; Tan 
et al., 1999; Wattanasirichaigoon et al., 2002).     
Exon 1 is one of the muscle-specific exons of TPM3. The missense mutation identified 
segregates completely with the disease in this large family with autosomal dominant NM. The 
mutation substitutes a highly conserved methionine with an arginine near the amino-terminus 
of γ-tropomyosin (Laing et al., 1995). The amino-terminus is crucial for actin binding, since 
the binding ability is completely inhibited by removal of the nine amino-terminal basic amino 
acid residues (Cho et al., 1990). Experiments with bacterially-expressed rat αTmfast and 
baculovirus systems in insect cells indicate that the γ-tropomyosin missense mutation reduces 
the actin-binding affinity of the protein (Akkari et al., 2002; Moraczewska et al., 2000) and 
might cause a local destabilisation of the tropomyosin coiled-coil (Moraczewska et al., 2000). 
The mutation has been shown to alter the tropomyosin dimer preference in skeletal muscle, 
reducing  γ/β heterodimer formation and increasing γ/γ homodimer formation in NM muscles. 
The altered dimer preference might play a role in the reduction of βTm expression seen in 
both NM patients and in transgenic mouse models with this mutation. Thus, reduction in the 
level of βTm could be used as an early clinical diagnostic marker for TPM3
 
mutations 
(Corbett et al., 2005). The mouse shows all the histological changes associated with this 
disorder including rod formation, a higher proportion of slow, oxidative fibres and muscle 
weakness. The onset of muscle weakness does not correlate with changes in fibre type and rod 
pathology (Corbett et al., 2001). In these mice, endurance exercise following immobilisation 
reduced muscle weakness and also reduced the number of nemaline rods in the extensor 
digitorum longus muscle. The slow recovery of the soleus muscle from stretch-induced 
muscle damage suggests that muscle regeneration in these mice is impaired (Joya et al., 
2004).   
In a severe case of NM a nonsense mutation was identified in the same muscle-specific 
exon 1 of TPM3. The patient was homozygous for the mutation introducing a premature stop 
codon. In this family the NM was probably inherited as a recessive trait. As no samples were 
available from the parents, this conclusion is inferred from the consanguinity of the parents 
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and the fact that the patient was homozygous for the mutation (Tan et al., 1999). As the 
patient was deceased no appropriate material was available, hence the effect of this mutation 
can only be speculated. The outcome might have been that no peptide was produced due to 
instability of the truncated mRNA (Czaplinski et al., 1998; Dietz, 1997), or alternatively a 
truncated 30 amino acid peptide might have been produced that would have prevented the 
proper formation of the polymer (Tan et al., 1999).  
Compound heterozygosity has been observed in a patient with two mutations in the 
muscle-specific exon 9b of TPM3. Samples from the parents confirm the recessive mode of 
inheritance. Mutations identified in this exon are a splice-site mutation predicted to prevent 
inclusion of exon 9b and a conversion of a stop codon into a codon for serine 
(Wattanasirichaigoon et al., 2002). The last nine amino acid residues of slow skeletal muscle  
γ-tropomyosin determine the binding affinity of unacetylated tropomyosin for actin (Hammell 
and Hitchcock-DeGregori, 1996). Furthermore, an intact exon 9b is required for the troponin 
complex to promote the high affinity of tropomyosin for actin. Thus, alteration of the 
carboxy-terminal sequences, such as the addition of a non-α-helical tail, is predicted to 
significantly alter the interaction between tropomyosin and actin in the filaments, possibly 
accounting for the nemaline body formation and muscle weakness in this patient 
(Wattanasirichaigoon et al., 2002). 
In a patient with atypical NM a de novo dominant missense mutation has been identified 
in the constitutively expressed exon 5 of TPM3. This mutation substitutes a highly conserved 
histidine residue with an arginine (Durling et al., 2002). The amino acid change likely alters 
the charge in the α-helical coiled-coil which in turn alters the thermodynamics of helix 
formation (O'Neil and DeGrado, 1990). The TPM3 gene is transcribed into eleven different 
products which are widely expressed in non-muscle tissues including brain. All these 
transcripts should be altered by the mutation in this patient (Dufour et al., 1998).  
 
 
3.3.2 The nebulin gene, NEB 
 
In 1999 Pelin and co-workers published the first six mutations identified at the 3´ end of 
NEB, associated with autosomal recessive NM. Homozygous mutations were found in 
patients of two families with consanguineous parents. One of these mutations is believed to 
result in the loss of the last 134 amino acids, including the SH3 and the serine-rich domain of 
nebulin. In the other family the child is homozygous for a mutation predicted to cause 
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abnormal splicing. Interestingly, this patient seems to express the carboxy-terminal SH3 
domain of the protein despite the presence of a stop codon in the aberrant transcript. In 
another family the two affected children were found to be compound heterozygotes for NEB 
mutations. In a further two families only one mutation was detected in the affected patients. 
Based on their haplotypes these patients are likely to be compound heterozygotes also (Pelin 
et al., 1999).  
A deletion of 2502 bp, causing skipping of exon 55, has been observed in the Ashkenazi 
Jewish population. The absence of this exon results in the generation of a transcript that 
encodes 35 fewer amino acids than the full-length transcript. This deletion causes the typical 
form of NM in patients homozygous for this mutation (Anderson et al., 2004). 
 
3.3.3 The skeletal muscle α-actin gene, ACTA1   
  
It has been estimated that approximately 15-25% of NM cases are due to missense 
mutations in the ACTA1 gene (Ilkovski et al., 2001). These are mainly dominant mutations 
although some recessive mutations have been identified. In most dominant cases the 
mutations have arisen de novo. Patients with ACTA1 mutations display clinical variability, 
ranging from severe congenital to adult onset NM (Ilkovski et al., 2001; Nowak et al., 1999). 
Severe cases are, however, more common among patients with ACTA1 mutations than they 
are among patients with NEB mutations (Ilkovski et al., 2001; Nowak et al., 1999; Pelin et al., 
2002; Pelin et al., 1999; Wallgren-Pettersson et al., 1999; Wallgren-Pettersson et al., 2004b). 
The amino acid residues encoded by exons 2-7 of ACTA1 are highly conserved, with an 
overall homology of 93% between human and drosophila proteins. Mutations have been 
identified at residues that interact with ATP/ADP, DNase I, myosin, α-actinin, α-actinin 2, 
tropomyosin and at residues that have ionic interactions with other parts of actin. All 
identified ACTA1 mutations causing NM cause replacement of amino acids that are conserved 
among known actins (Ilkovski et al., 2001; Nowak et al., 1999). A family with autosomal 
dominant NM has a mutation at an implied α-actinin 2-binding site in exon 3. The variation in 
both age of onset and clinical severity among the patients in this family suggests that 
modifying genetic or environmental factors might influence the clinical presentation (Ilkovski 
et al., 2001). In another family with a severe form of NM a mutation has been observed at a 
DNase-binding site in exon 4. In this family the unaffected father is a somatic mosaic for the 
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mutation (Nowak et al., 1999). Somatic mosaicism has so far been observed in two of nearly 
80 families in which ACTA1 mutations have been identified (Sparrow et al., 2003).    
The pathogenesis of muscle weakness and hypotonia in patients with mutations in 
ACTA1 is unknown, although disruption of actin structure and interactions are likely to impair 
myofibre contractility. As in other forms of NM, the proportion of fibres containing rods does 
not seem to correlate with disease severity, although there is some correlation with the 
proportion of fibres occupied by rods, the size of the rod clusters, the organisation of 
sarcomeric actin and the degree of myofibrillar disruption. A common feature in some of the 
patients is altered expression of fibre-type specific genes. This suggests either fibre type 
conversion or an abnormal maturation of the fibres. In patients with severe congenital NM, 
abnormal expression of tropomyosin and nebulin was reported. As these proteins are closely 
associated with thin-filament actin it seems likely that mutations in ACTA1 may affect nebulin 
and tropomyosin distribution (Ilkovski et al., 2001).  
Skeletal muscle α-actin and cardiac α-actin are co-expressed in striated muscle. Cardiac 
α-actin is thought to be the major actin isoform present in embryonic skeletal muscle. It is 
rapidly replaced by skeletal α-actin during the postnatal period (Collins et al., 1997). The 
expression of cardiac α-actin might explain why two patients with severe congenital NM 
survived to term but exhibited severe hypotonia and absence of antigravity movements from 
birth (Ilkovski et al., 2001). Skeletal actin null mice survive to term but die during the early 
neonatal period. In newborn animals an upregulation of cardiac and vascular actin mRNA has 
been observed (Crawford et al., 2002). A recessive mode of inheritance has been described in 
a consanguineous Gypsy family with a nonsense mutation in ACTA1. In this family the 
patient, homozygous for the mutation, presented generalised hypotonia and absence of 
spontaneous movements and required respiratory assistance from birth (Romero et al., 2003). 
This mutation is also predicted to cause absence of skeletal muscle actin (Okamoto et al., 
1986; Sparrow et al., 2003). The recessive nature of this mutation indicates that one wild-type 
copy of ACTA1 is sufficient for normal muscle function (Sparrow et al., 2003). This is 
supported by the fact that mice hemizygous for skeletal actin are fully viable (Crawford et al., 
2002). There is evidence that the dominance of the vast majority of ACTA1 mutations is due 
to a dominant negative effects of mutant actin. NM-causing mutations have been shown to 
cause altered polymerisation and abnormal folding of actin and aggregation of actin within the 
cytoplasm and nucleus (Ilkovski et al., 2004).  
In human fetal heart, cardiac α-actin is the prevalent isoform, whereas skeletal α-actin 
predominates in the adult heart. None of the NM patients with mutations in the skeletal 
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α-actin gene have detectable clinical abnormalities of cardiac muscle contractility, although 
mutations in cardiac α-actin result in dilated cardiomyopathy (Olson et al., 1998). The 
presence of one normal ACTA1 allele might be adequate for normal cardiac muscle function 
(Ilkovski et al., 2001).      
 
3.3.4 The troponin T1 gene, TNNT1 
 
A recessive nonsense mutation in the gene encoding slow skeletal muscle troponin T 
(TNNT1) has been reported to segregate with an unusual, severe form of NM among the Old 
Order Amish. This is a distinct form of NM, differing clinically from all other known NM 
cases in that all neonates have tremor, evident at birth, involving most skeletal muscle groups. 
The mutation has been traced back to a putative founder couple born in the first half of the 
18th century (Johnston et al., 2000). Immunohistochemistry on muscle biopsies of ANM 
patients showed that neither intact nor a truncated slow TnT protein was present. This is 
consistent with the recessive pattern of inheritance and indicates a critical role of the carboxy-
terminal domain in integration of TnT into myofibrils (Jin et al., 2003).  
Results of neuromuscular examinations of parents and healthy siblings are 
unremarkable. However, several siblings with normal outcomes have had abnormal tremor 
both in utero and for weeks after birth. The results of neurological examinations were 
otherwise normal in these siblings. These findings suggest the presence of subtle clinical 
manifestations in carriers, although these persons have been considered unaffected (Johnston 
et al., 2000).  
Despite the lack of slow TnT, ANM patients have normal muscle power at birth. The 
postnatal onset and infantile progression of the disease corresponds to a down-regulation of 
cardiac and embryonic splice variants of  TnT, and suggests that fetal TnT might complement 
for the loss of slow TnT during early development (Jin et al., 2003).   
A variety of mutations causing hypertropic cardiomyopathy have been identified in the 
corresponding gene for cardiac TnT, TNNT2. A splice-site mutation in intron 16 is predicted 
to lead to production of a truncated protein (Perry, 1998). Transfection studies of this 
mutation indicate that expression of truncated TnT may have a dominant negative effect on 
muscle (Perry, 1998; Watkins et al., 1996). While mutations in TNNT1 manifest in an 
autosomal recessive pattern, TNNT2 mutations segregate in an autosomal dominant pattern. 
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This might be because skeletal and cardiac muscles may have different phenotypic thresholds 
(Johnston et al., 2000). 
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4 Other diseases caused by mutations in cardiac and skeletal muscle thin filament genes 
 
In addition to NM, mutations in genes encoding proteins of the skeletal muscle thin 
filament have been reported to cause actin myopathy, congenital fibre type disproportion, 
intranuclear rod myopathy and distal arthrogryposes. Cardiac paralogues to skeletal thin 
filament genes cause three different diseases of the heart: hypertrophic cardiomyopathy, 
dilated cardiomyopathy and restrictive cardiomyopathy. Mutations in the same skeletal or 
cardiac thin filament gene, can often cause more than one disease (Table 1).   
 
 
 
Table 1. Cardiac and skeletal thin filament genes and associated diseases 
 
Gene  Locus Disease  Protein  Reference 
ACTA1 1q42.13-
q42.2 
NM, AM, CFTD 
and IRM  
actin, alpha 1, skeletal 
muscle 
Nowak et al. 1999, Sparrow et al. 
2003, Laing et al. 2004 
ACTC 15q11-q14 HCM and DCM actin, alpha, cardiac 
muscle 
Olson et al. 2000, Olson et al. 
1998 
NEB 2q21.2-q22 NM nebulin Pelin et al. 1999, Pelin et al. 2002 
TPM1 15q22.1 HCM and DCM tropomyosin 1 (alpha) Olson et al. 2001, Thierfelder et 
al. 1994  
TPM2 9p13.2-
p13.1 
NM and DA tropomyosin 2 (beta) Donner et al. 2002, Sung et al. 
2003 
TPM3 1q21.2-q23 NM and papillary 
thyroid carcinoma * 
tropomyosin 3 Tan et al. 1999 
TNNC1 3p21.3-
3p14.3 
HCM and DCM troponin C, slow, cardiac Hoffman et al. 2001, Mogensen et 
al. 2004 
TNNI2 11p15.5 DA troponin I, skeletal, fast Sung et al. 2003 
TNNI3 19q13.4 HCM, DCM and 
RCM  
troponin I, cardiac Kokado et al. 2000, Murphy et 
al.2004, Mogensen et al. 2003 
TNNT1 19q13.4 NM  troponin T1, skeletal, 
slow 
Johnston et al. 2000 
TNNT2 1q32 HCM and DCM troponin T2, cardiac Gomes et al. 2004, Moolman et 
al. 1997, Mogensen et al. 2004 
     
NM, nemaline myopathy; AM, actin myopathy; CFTD, congenital fibre type disproportion; IRM, 
intranuclear rod myopathy; HCM, hyperthropic cardiomyopathy; DCM, dilated cardiomyopathy; DA, distal 
arthrogryposes ; RCM, restrictive cardiomyopathy. 
 
* caused by intrachromosomal inversions rearranging TPM3 and NTRK1, papillary thyroid carcinoma 
frequently displays oncogenic rearrangements of the NTRK1 gene. 
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4.1 Actin myopathy, congenital fibre type disproportion and intranuclear rod myopathy  
 
Actin myopathy (AM), congenital fibre type disproportion (CFTD) and intranuclear rod 
myopathy (IRM) are muscle diseases caused by mutations in ACTA1.  
AM has been described as a congenital myopathy with an excess of thin filaments. 
Muscle biopsy reveals homogeneous filamentous inclusions containing actin, occupying areas 
devoid of sarcomeres, which would normally be part of the myofibrillar filament lattice 
(Goebel et al., 1997a; Goebel et al., 2004; Goebel et al., 1997b; Goebel and Warlo, 1997; 
Nowak et al., 1999). Many patients with accumulations of thin filaments also show nemaline 
bodies (Goebel et al., 2004).  
CFTD is a rare form of congenital myopathy. The first description was of 12 children 
with early-onset general weakness and type 1 muscle fibres that were at least 12% smaller 
than type II fibres (Brooke, 1973). This histological appearance can also be seen in other 
neuromuscular conditions, i.e. NM, making exclusion of other known causes important 
(Clarke and North, 2003). Three heterozygous missense mutations in ACTA1 have been 
identified in three unrelated patients. All these mutations are in the same general region of the 
molecule and are predicted to disrupt interaction between actin and tropomyosin (Laing et al., 
2004).  
IRM is characterised by, as the name implies, intranuclear inclusions (Barohn et al., 
1994; Goebel et al., 1997b). The patients with IRM fall into two categories; adults and young 
infants with an usually severe form of the disease (Goebel and Warlo, 1997). Severe NM is 
sometimes associated with intranuclear nemaline rods (Nowak et al., 1999), and IRM has 
been called a rare and morphologically striking variant of NM (Weeks et al., 2003). In a study 
by Goebel et al. (1997a), two of three AM patients had intranuclear rods.   
It has been predicted that all ACTA1 mutations causing AM will affect nucleotide 
binding and/or hinge flexibility. Similarly most IRM mutations seem likely to affect the same 
functions of skeletal α-actin. Only one mutation causing NM is predicted to affect either of 
these functions. Since mutations causing AM and IRM affect similar aspects of actin function, 
it is unclear why the histological phenotypes, especially the nuclear rods, in most cases are so 
distinct (Sparrow et al., 2003).    
 
 
 43 
4.2 Distal arthrogryposes  
 
Distal arthrogryposes (DAs) are characterised by nonprogressive, multiple congenital 
contractures (i.e., arthrogryposes) of two or more different body areas without primary 
neurological and/or muscle disease affecting limb function. Features which are common to all 
DAs include a pattern of distal joint involvement, limited proximal joint involvement, an 
autosomal dominant inheritance pattern, and widely variable expressivity. DAs have been 
subdivided into ten different categories according to the proportion of features shared among 
the patients (Bamshad et al., 1996). Mutations in TPM2 and TNNI have been reported to cause 
DA1 and DA2B, respectively. The missense mutation identified in TPM2 in one family 
causes a non-conservative amino acid substitution. This substitution is predicted to cause a 
local reduction in surface charge that may alter both the local conformation of the coiled-coil 
and its rigidity. In TNNI2 missense and nonsense mutations have been observed. In one 
family the segregation of a nonsense mutation suggests either mosaicism or that the mutation 
would have arisen de novo twice. These mutations might lead to a diminished responsiveness 
to Ca+2 ions, leading to reduced muscle contraction and congenital contractions (Sung et al., 
2003).   
 
4.3 Hypertrophic cardiomyopathy  
 
Hypertrophic cardiomyopathy (HCM) is one of the most frequently occurring inherited 
cardiac disorders, being the most common cause of sudden death in young adults (Maron et 
al., 1995). It is characterised by ventricular hypertrophy, with predominant involvement of the 
interventricular septum, accompanied by myofibrillar disarrays. It is estimated that 60-70% of 
all HCM cases are familial, the disorder being most often inherited as an autosomal dominant 
trait. At least 13 genes have been implicated as causing HCM (Chien, 2003; Marian, 2001; 
Seidman and Seidman, 2001). These genes include TNNT2, TNNI3, TNNC1, TPM1, and 
ACTC (Gomes and Potter, 2004; Hoffman et al., 2001; Jääskeläinen et al., 1998; Karibe et al., 
2001; Kimura et al., 1997; Kokado et al., 2000; Moolman et al., 1997; Olson et al., 2000; 
Olson et al., 2001; Regitz-Zagrosek et al., 2000; Song et al., 2005; Thierfelder et al., 1994; 
Watkins et al., 1995a). It has been estimated that TNNT2 mutations account for approximately 
15% of all HCM cases (Watkins et al., 1995b).  
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Mutations in the α-tropomyosin gene, TPM1, is a rare cause of HCM (Karibe et al., 
2001; Olson et al., 2001; Regitz-Zagrosek et al., 2000; Thierfelder et al., 1994; Watkins et al., 
1995a). Interestingly, TPM1 mutations account for over 11% of cases in the Finnish 
population (Jääskeläinen et al., 1998). Most of these are due to a few founder mutations 
(Jääskeläinen et al., 2004; Jääskeläinen et al., 1998). Mutations in this gene seem to be 
positioned at distinct heptad repeats in the molecule (Brown et al., 2001; Jongbloed et al., 
2003; Michele and Metzger, 2000).  
Mutations in the cardiac actin gene, ACTC, account for less than 1% of HCM cases. 
Most mutations causing HCM are likely to affect actin-myosin interaction and force 
generation (Olson et al., 2000).        
 
4.4 Dilated cardiomyopathy  
  
Dilated cardiomyopathy (DCM) is characterised by dilatation of the left ventricular 
cavity and systolic dysfunction in the absence of other known causes (Dec and Fuster, 1994). 
Of all DCM cases, 20-30% show inheritance of the disease as an autosomal dominant, X-
linked recessive, or mitochondrial genetic trait (Keeling et al., 1995; Mestroni and Giacca, 
1997; Michels et al., 1992; Muntoni et al., 1993; Towbin et al., 1993). Recessive inheritance 
has been proposed for 16% of affected families (Towbin and Bowles, 2001). Mutations in 
ACTC, TPM1, TNNC1, TNNT2 and TNNI3 have been associated with this disease (Hanson et 
al., 2002; Li et al., 2001; Mogensen et al., 2004; Murphy et al., 2004; Olson et al., 2001; 
Olson et al., 1998). Interestingly, these are the same five genes that also cause HCM. 
Mutations in TPM1 alter amino acids that are positioned in a distinct heptad repeat (distinct 
from those causing HCM) of α-tropomyosin (Brown et al., 2001; Olson et al., 2001). These 
mutations are believed to create a locally increased positive charge in the negatively charged 
surface of the molecule, probably changing the electrostatic interaction between actin and 
tropomyosin filaments (Olson et al., 2001).  
DCM-causing missense mutations and deletions have been identified in TNNT2 (Hanson et 
al., 2002; Li et al., 2001; Mogensen et al., 2004). Mutations in TNNT2 occur in well-
conserved regions essential for interactions within the troponin complex or for interactions 
with tropomyosin or actin (Hinkle et al., 1999; Hinkle and Tobacman, 2003; Perry, 1998; 
Perry, 1999; Perry, 2001; Rarick et al., 1999; Solaro and Rarick, 1998). 
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4.5 Restrictive cardiomyopathy  
 
Restrictive cardiomyopathy (RCM) is a myocardial disease characterised by impaired 
ventricular filling and reduced diastolic volume. The systolic function is normal and the 
myocardial thickness is normal or near normal (Richardson et al., 1996). The disease is 
characterised by symptoms of progressive heart failure. The prognosis is poor, especially 
when onset is in childhood, and patients often require heart transplantation (Rivenes et al., 
2002). Altogether six different missense mutations have been identified in the cardiac 
troponin I gene (TNNI3) causing RCM. All these mutations occur in conserved regions of the 
gene, encoding functionally important regions of the protein (Perry, 1999). Two of the 
mutations alter amino acids located at the region required for inhibition of human cardiac 
troponin I actomyosin ATPase activity. The remaining mutations affect regions close to or 
within other important troponin I domains. In a large pedigree a mutation segregates in a 
dominant pattern while two of the patients seem to have de novo dominant mutations. In three 
of the cases the mode of inheritance could not be determined (Mogensen et al., 2003).            
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AIMS OF THE STUDY 
 
 
At the beginning of this study, mutations in four genes, TPM3, NEB, ACTA1 and TNNT1, 
were known to cause NM. Linkage studies in some families indicated that there had to be at 
least one as yet unidentified gene causing the disorder. At the time, the complete genomic 
structure of NEB was unknown, and exons undergoing alternative splicing remained to be 
characterised. 
 
 
The specific aims of this study were to: 
 
1. identify new genes underlying NM 
2. reveal the complete genomic organisation of NEB 
3. characterise alternative transcripts produced by human NEB 
4. elucidate the developmental and muscle type-specific expression of mouse Neb exons 
127 and 128 corresponding to the alternatively spliced human exons 143 and 144 
5. detect new mutations in NEB causing nemaline myopathy  
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MATERIALS AND METHODS 
 
 
NM patients, families, control individuals and tissues 
 
Altogether 66 unrelated patients from 16 different countries and 77 families of various ethnic 
origins were included in the mutational analyses of TPM2 and NEB, respectively. Control 
DNA samples from anonymous blood donors were provided by the Finnish Red Cross Blood 
Transfusion Service and Centre d´Etude du Polymorphisme Humain.    
 
Studies including patients (I and IV) have been approved by the Ethics Committee for 
Pediatrics, Adolescent Medicine and Psychiatry, University of Helsinki. Patients were 
included in the study with the permission of their guardians.  
 
 
 
Table 2. Methods used in the original articles included in this thesis. The numbers of the 
original publications in which the method was used are indicated. 
 
Method Publication 
  
DNA extraction I, IV 
PCR I, II, III, IV 
RNA extraction I, II, III, IV 
SSCP I, IV 
Sequencing I, II, III, IV 
Silver staining I, IV 
Reverse-transcriptase PCR (RT-PCR) I, II, III, IV 
Haplotype analysis I, IV 
BLAST homology searches II 
BioEdit sequence alignment II 
EST alignment II 
RepeatMasker II 
NIX analysis II 
SMART protein tool analysis II 
Recombinant DNA techniques (cloning) II 
Semiquantitative PCR II 
Statistical analysis III  
Computer analysis III 
Real-time quantitative PCR III 
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RESULTS AND DISCUSSION 
 
 
1 Mutations in the β-tropomyosin gene, TPM2 – a rare cause of NM (Study I and 
unpublished data) 
 
When this study was initiated, linkage studies had indicated that at least one further gene 
in addition to the previously reported TPM3, NEB, ACTA1 and TNNT1 genes was responsible 
for NM. Since γ-tropomyosin, encoded by TPM3, was known to function in close proximity 
with β-tropomyosin, encoded by TPM2, in the thin filaments of the muscle sarcomere, we 
speculated that TPM2 was a good candidate for mutation analysis in NM patients. Two 
autosomal dominant mutations were identified in this gene. In a Bosnian boy aged 4 years, a 
heterozygous missense mutation changing a glutamic acid (E) to lysine (K) was identified in 
exon 3. This mutation was also present in the affected mother, but not in the healthy maternal 
grandparents of the index patient, indicating that this is a dominant mutation which has arisen 
de novo in the mother. The NM diagnosis could not be verified in this family because of 
uncertainty regarding the presence of nemaline bodies in the muscle biopsy. It is, however, 
known that the quantity of nemaline bodies can vary substantially between and even within 
the muscles of an individual patient (Wallgren-Pettersson and Clarke, 1996). Nemaline bodies 
have in some cases only been detected in a second biopsy, which was not available for this 
family.   
In a Dutch patient with mild NM a heterozygous missense mutation changing a 
glutamine (Q) to proline (P) was detected in exon 4. Samples from seven unaffected siblings 
and the patient’s unaffected mother were available. The mutation was not present in the 
mother. Three of the healthy siblings did not have the mutation but had the same paternal 
haplotype for flanking markers, indicating that this mutation had also arisen de novo. The 
patient died at age 51 from respiratory causes.  
The function of tropomyosin in skeletal and cardiac muscle is in stabilising the thin 
filament, and in association with the troponin complex, to regulate the calcium-sensitive 
interaction of actin and myosin during muscle contraction (Clark et al., 2002a; Ebashi et al., 
1969; Farah and Reinach, 1995; Greene and Eisenberg, 1980). Comparative amino and 
nucleic acid analyses of different tropomyosin isoforms in skeletal muscle, cardiac muscle, 
smooth muscle and non-muscle cells prove these proteins to be highly conserved among 
vertebrates (Helfman et al., 1999) (Figure 6).  
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TPM2 Wild type human    EEAEKAADESERGMKVIENRAMKDEEKMELQEMQLKE 
   NM patients (Bosnian)   ---K--------------------------------- 
   NM patient (Dutch)   ---------------------------------P--- 
   Rabbit     ------------------------------------- 
   Mouse     ------------------------------------- 
   Chicken     ------------------------------------- 
   Frog      --T---V--------------T------VD--Q--R- 
   Fish      ---------------------S---------DI---- 
TPM1       ------------------S--Q-------I--I---- 
TPM3       ---------------------L----------I---- 
 
 
 
Figure 6. Comparison of tropomyosin amino acid sequences of two patients and various 
vertebrates. Invariant amino acids are shown as lines. Mutations identified in NM patients are 
located at highly conserved residues (shaded in grey). The corresponding sequences of  TPM1 
and TPM3 are shown in the last two lines. The arrow indicates the border between amino 
acids encoded by exon 3 (left of the arrow) and amino acids encoded by exon 4 (right of the 
arrow). The arginine (R) located at the arrow is encoded by both exons. 
 
The nature of the mutation (E to K) in the Bosnian family resembles that of a mutation 
in TPM3. This mutation also changes a conserved acidic residue to a basic residue adjacent to 
existing basic residues (Laing et al., 1995). These analogies with the TPM3 mutation are in 
concordance with the interpretation that this mutation is disease-causing. The main effects of 
the TPM3 mutation are weaker actin affinity, local destabilisation of the tropomyosin 
coiled-coil dimer and altered tropomyosin dimer preference (Corbett et al., 2005; 
Moraczewska et al., 2000).  
The Dutch mutation changes a highly conserved glutamine to a proline, a known helix-
breaker. Proline is not present in any wild-type tropomyosin, at any amino acid position, 
which is in agreement with the α-helical coiled-coil structure of tropomyosin, and verifies the 
interpretation that this is also a disease-causing mutation. This mutation probably also alters 
the actin-binding properties of the β-tropomyosin molecule and causes local disruption of the 
α-helical coiled-coil dimer. 
Three of four tropomyosin genes, i.e. TPM1, TPM2 and TPM3, produce multiple 
products using alternative splicing. Some exons are constitutively spliced into all transcripts 
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of the gene, while others have a more restricted expression pattern, including exons with 
preferred expression in skeletal muscle (Dufour et al., 1998).  
In TPM3 and TPM1 mutations in constitutively expressed exons have been identified as 
causing NM and HCM, respectively (Durling et al., 2002; Regitz-Zagrosek et al., 2000; 
Thierfelder et al., 1994). Both mutations identified in TPM2 are located in constitutively 
expressed exons (Figure 7).  
 
 
                                                 
 
 
 
Figure 7. Schematic view of tropomyosin genes. Mutations causing hypertrophic 
cardiomyopathy (HCM), dilated cardiomyopathy (DCM) and nemaline myopathy (NM) are 
indicated with arrows. Muscle-specific exons are coloured black and non-muscle-specific 
exons grey. Constitutively expressed exons are white. 
 
 
Studies of rodent tropomyosin isoforms indicate that transcripts encoded by these genes 
are also expressed in other than skeletal and cardiac muscles (Pittenger et al., 1995; Schevzov 
et al., 2005). It remains a mystery why the phenotypes are restricted to muscle in individuals 
with mutations in constitutively expressed exons. The impact of the mutation may depend on 
the function of specific filaments or specific proteins with which they interact. HCM- and 
DCM-causing mutations in TPM1 are positioned at an “e” or “g” position of the alpha-helical 
heptad repeat “abcdefg” which exists along the entire length of the tropomyosin molecules 
(Brown et al., 2001; Jongbloed et al., 2003; Michele and Metzger, 2000). Interestingly, the 
1a    2b    1b    3      4      5    6a    6b   7      8      9a    9b    9c     9d  
TPM1: HCM 
TPM1: DCM 
TPM2: NM 
TPM3: NM 
          A63V 
       E117K 
 D175N E180G/V 
Q147P 
     K70T  
   M9R  Q31X      R167H  Splice site   X285S 
           E40K E54K 
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mutations identified in the TPM2 gene are also in position “e” (E117K) and “g” (Q147P) of 
the heptad repeats. Positions “e” and “g” are close to the interface, i.e. positions “a” and “d”, 
between two α-helices. Furthermore, salt links between residues “e” and “g” on neighbouring 
chains provide additional stabilisation to the coiled-coil dimer (Brown et al., 2001).  
An alternative explanation might be that the large number of non-muscle tropomyosin 
isoforms encoded by other genes could compensate for the mutated isoforms in non-muscle 
tissue (Durling et al., 2002).  
Although 66 unrelated patients were screened for mutations only two mutations were 
found. No families with NM showing linkage to this gene or any novel mutations in the gene 
have been identified following this screen. This fortifies the prediction that mutations in 
TPM2 are a rare cause of NM. 
 
2 The nebulin gene, NEB  
 
2.1  Genomic organisation of NEB (Study II) 
 
The determination of the complete genomic structure of human NEB was a prerequisite 
for the initiation of molecular studies of the alternatively spliced exons. The primary protein 
structure of human nebulin, published by Labeit and Kolmerer in 1995, was based on a 20.8 
kb cDNA sequence and described nebulin as a repetitive molecule with 97% of the mass 
consisting of 185 copies of approximately 35-residue modules. The central 154 copies are 
grouped into 22 seven-module super repeats corresponding to 38.5 nm thin filament repeats. 
Outside the super-repeat region distinct module arrangements could be observed, implying 
functional diversity within the molecule (Labeit and Kolmerer, 1995a).      
As the completion of the human genome project released the sequences of 3 billion base 
pairs that make up human DNA, the complete genomic structure of human NEB could be 
determined. Two bacterial artificial chromosome (BAC) clones homologous to human NEB 
mRNA were revealed in a search through GenBank, one covering the 5´ end to the middle of 
super repeat 15 and the other covering the sequence from the middle of super repeat 15 to the 
3´ end of the gene. A total of 183 exons were identified in the genomic sequence (Figure 8). 
Analysis of the exons and the exon-intron boundaries revealed that the translation initiation 
codon is in exon 3 while exon 183 harbours the stop codon and the 3´ untranslated region 
(UTR). The total length of the genomic sequence spanning NEB is 249 kb. The exon lengths 
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range from 42-596 bp and the intron sizes from 83-9232 bp. The splice junctions of all introns 
follow the GT-AG rule. There are four regions of alternative splicing in NEB. These are exons 
63-66, 82-105, 143-144 and 166-177.  
Exons 166-177 encode simple repeat domains, which extend into the Z-disc. The central 
region of the gene harbours an approximately 8.2 kb region spanning eight exons, 82-89, 
apparently duplicated twice making up exons 90-97 and 98-105.  
 
   
 
Figure 8. Complete genomic structure of human NEB 
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The duplicated regions, i.e. exons 82-89, 90-97 and 98-105, have an overall homology 
of 99% and end with repetitive long interspersed nuclear elements (LINE-2) in introns 89, 97 
and 105. The duplicated exons were found in fetal NEB mRNA, in two expressed sequence 
tag (EST) sequences. Exons 82-105 encode 1458 amino acids, corresponding to 42 simple 
repeat or six super repeat domains.  
Human NEB is larger than the corresponding mouse gene (Neb), which was reported by 
Kazmierski and co-workers (2003) to have 165 exons in a 202 kb region. When the complete 
genomic structure of human NEB was determined it was compared with that of mouse Neb. A 
mouse exon homologous to human exon 143 was identified between mouse exons 126 and 
127. This exon was not reported by Kazmierski and co-workers. The expression of this exon 
was confirmed by reverse transcriptase (RT)-PCR and sequencing of adult and fetal mouse 
muscle RNA. The organisation of the human and mouse nebulin genes are similar, with the 
exception that the copies of human exons 82-89, that is exons 90-105, and exons 173 and 174 
are not present in the mouse gene. The mouse and human nebulin exon sizes and the protein 
domains encoded by the exons are similar up to exon 89. The LINE-2 elements, believed to 
be responsible for the duplication event in the human gene, are not present in the 
corresponding mouse introns. Furthermore, the mouse gene lacks two of the alternative exons 
encoding the Z-disc region simple repeats, that is, exons corresponding to human exons 173 
and 174. Altogether, human NEB has 18 exons not present in mouse Neb. Interestingly, 
mouse Neb has one exon (exon 130) not present in human NEB. This exon is homologous to 
human tight junction protein, ZO-1 (Kazmierski et al., 2003).  
Partial genomic sequence of rat Neb revealed that the duplicated human exons 82-89 
and the intronic LINE-2 sequence are present in this paralog. Rat Neb contains two exons 
corresponding to human exon 169 and lacks an exon corresponding to mouse exon 130, i.e. 
the exon homologous to human tight junction protein. However, similarly to the mouse gene, 
the rat gene lacks exons corresponding to human exons 173 and 174.  
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2.2  Alternative nebulin transcripts in human muscles (Study II) 
 
It has been estimated that nearly 60% of all human genes are alternatively spliced 
(Lander et al., 2001). Alternative splicing is often regulated in a developmental or 
tissue-specific manner. In muscle this is a common mechanism used to create proteins 
specific for different muscle types and muscles at different developmental stages (Bang et al., 
2001a; Buj-Bello et al., 2002; Durling et al., 2002; Ladd et al., 2001; Selvakumar and 
Helfman, 1999; Standiford et al., 2001). Splicing is in many cases controlled by exonic (Guo 
et al., 1993; Humphrey et al., 1995; Watakabe et al., 1993) or intronic (Balvay et al., 1992; 
Guil et al., 2003; Huh and Hynes, 1993; Ryan and Cooper, 1996; Wei et al., 1997) cis-acting 
RNA sequences that negatively or positively regulate the selection of the splice site (Hastings 
and Krainer, 2001; Smith and Valcarcel, 2000). The specificity and efficiency of the splicing 
event is controlled by the binding of specific proteins to these regulatory sequences (Guil et 
al., 2003).   
The alternatively spliced exons 63-66 of NEB are located in the central super repeat area 
of nebulin, encoding a protein repeat module highly homologous to super repeat 11 (Pfuhl et 
al., 1996). Adult human muscle expressed a transcript lacking exons 63-66, corresponding to 
the transcript described by Labeit and Kolmerer (1995a). In human fetal muscle, only longer 
transcripts including all alternatively spliced exons from this region, i.e. exons 63-66, were 
identified. Interestingly, the length of these exons corresponds to the length of a seven-module 
super repeat.  
The duplicated region, that is, exons 82-105, in the central region of NEB encodes six 
super repeats in addition to the 22 super repeats reported by Labeit and Kolmerer (1995a). 
The extreme homology between and the length of these duplicated regions complicated the 
elucidation of the transcripts encoded by them. We were able to amplify and sequence exons 
82, 83 and 105 from adult skeletal muscle cDNA. Longer products were observed, indicating 
expression of several of the exons 82-105. Expression of exons 80-106 could not be detected 
in human cardiac muscle, which would be in agreement with the expression of shorter nebulin 
isoforms in heart muscle .   
The 3´ end of NEB harbours two regions with alternatively spliced exons. These are 
exons 143-144 and exons 166-177. Exons 143 and 144 encode two different transcripts, i.e. 
transcripts expressing exon 143 or transcripts expressing exon 144 (Figure 9).  
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Figure 9. Alternative splicing of exons 143 and 144 gives rise to two different mRNA 
transcripts (top and bottom). These mutually exclusive exons encode amino acid sequences 
that differ in charge and hydrofobicity. Exons 143 and 144 correspond to mouse exons 127 
and 128. 
 
 
Human fetal muscle expresses only transcripts expressing exon 143, while adult human 
gastrocnemius, rectus femoris and cardiac muscle express only transcripts expressing exon 
143. Both transcripts were observed in human tibialis anterior muscle. Exons 143 and 144 
encode amino acid sequences that differ in both charge and hydrophobicity. No transcripts 
expressing both exon 143 and exon 144 were identified in any of the muscles studied. The 
amino acid sequence encoded by exon 143 shows complete homology between human, rat 
and mouse, indicating a conserved role for this region of the protein.  
Exons 166-177, encoding Z-disc region simple repeats, undergo extensive alternative 
splicing, giving rise to a multitude of transcripts. The use of a variety of transcripts was 
observed in both human and mouse muscles. Twenty different transcripts were identified in 
the human tibialis anterior alone (Figure 10).  
 
Exon 145 Exon 144 Exon 142 
Exon 145 Exon 143 Exon 142 
Exon142 Exon 143 Exon 144 Exon 145 
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Figure 10. RT-PCR of different muscle RNAs, demonstrating extensive alternative splicing of 
the region including differentially expressed human exons 166-177 and the corresponding 
mouse exons, i.e. 150-160. Differently sized RT-PCR products were isolated from agarose 
gel, cloned and sequenced to reveal the nucleotide composition of different transcripts.   
 
 
Exons 166-177 resemble the centrally located exons 82-105 in that the alternative exons  
encode highly homologous simple repeats and super repeats, respectively.  
Transcripts encoded by nebulin exons 143 and 144 differ from the other alternative 
transcripts in that the amino acid sequences encoded by the two transcripts are remarkably 
different and/or in that the amino acid sequence encoded by one of the exons has been 100% 
conserved during evolution. The reason for this might be that the simple repeats encoded by 
these exons harbour a regulatory function not present in the simple repeats encoded by other 
alternatively spliced regions of the gene.  
 
2.3  Alternative splicing of mouse Neb exons 127 and 128 (Study III) 
 
The expression pattern of transcripts encoded by exons 143 and 144 of human NEB was 
shown to vary between different muscles and muscles at different developmental stages. To 
further elucidate the expression of these two transcripts we quantified the corresponding 
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transcripts, i.e. transcripts encoded by mouse exons 127 and 128, in nine different muscles 
ranging from neonatal to 6-week-old mice. 
The relative abundance of the two transcripts, quantified by quantitative real-time PCR, 
showed identical patterns of expression in tibialis anterior, gastrocnemius, extensor digitorum 
longus and quadriceps muscles. In all these hind leg muscles transcripts expressing exon 127 
were more prominent in muscles from younger mice, while the corresponding muscles of 
older mice expressed higher quantities of the transcript expressing exon 128. This transcript 
was the most common in all muscles in the most mature muscles studied, i.e. the muscles 
from 6-week-old mice (Figure 11).     
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Figure 11. Two transcripts encoded by exons 127 and 128 show identical patterns of 
expression in gastrocnemius, tibialis anterior, extensor digitorum longus and quadriceps. 
These are all hind leg muscles. The relative abundance of the two transcripts were quantified 
by quantitative real-time PCR in muscles from neonatal to 6-week-old mice. For quadriceps 
only 23-day-old and 4- and 6-week-old muscles were available.   
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Human gastrocnemius muscle expressed only the transcript expressing exon 144, 
corresponding to mouse exon 128. While this seems to be the most prominent transcript in 
6-week-old mouse muscles, in neonatal to 19-day-old mouse muscles the transcript 
expressing exon 127 is the most common (Figure 11). This might be explained by the fact that 
the human samples used in the previous study were from adult muscle and the method used 
for transcript detection was less sensitive. The 6-week-old mouse gastrocnemius muscle, 
however, clearly also expresses the transcript not found in the corresponding human muscle.  
The expression levels of the two transcripts in the fetal mouse suggest that the 127 
transcript is the more common one during early differentiation. The expression pattern of the 
soleus might be in contradiction to this suggestion. It seems that 128 transcripts are common 
in both 4-day-old and adult mice, while higher quantities of the 127 transcript can be observed 
in 14, 19, 21 and 23-day-old mice  (Figure 12). 
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Figure 12. In the soleus muscle the expression pattern of transcripts expressing exons 127 and 
128 differ from the other hind leg muscles studied. Quantitative real-time PCR demonstrates 
that the 128 transcript is common in both 4-day-old (no neonatal samples were available) and 
adult mice, while higher quantities of the 127 transcript can be observed in 14 to 23-day-old 
mice.  
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The expression pattern of the 4-, 7- and 14-day slow-twitch soleus muscle differs from 
all other postnatal hind leg muscles studied. In these developmental stages the relative 
expression of the 128 transcript is high in 4-day-old muscle, after which it decreases. The 
lowest level of this transcript is observed in 19-day-old muscle. To fully reveal the 
developmental expression pattern in this muscle, embryonic muscle would be needed.  
The diaphragm and masseter mainly express the 128 transcript. The expression of one 
prominent transcript in diaphragm and masseter might be explained by substitution of one 
transcript for another in these muscles earlier during differentiation (Figure 13).  
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Figure 13. Diaphragm, masseter and longus capitis mainly express one of the two transcripts. 
An earlier substitution (compared to gastrocnemius, tibialis anterior, extensor digitorum 
longus and quadriceps) of transcripts might explain why diaphragm and masseter mainly 
express the exon 128 transcript. In longus capitis the transcript expressing exon 127 is 
predominant at all time points tested, and a transcript switch does not seem to take place in 
this muscle. 
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Diaphragm and masseter express both transcripts in neonates and in 4- and 7-day-old 
mice, although the 128 transcript is more common. While the substitution of one transcript for 
another earlier in differentiation might explain why these muscles mainly express the 128 
transcript, it seems unlikely that this would explain why the longus capitis muscle almost 
exclusively expresses the 127 transcript (Figure 13). The earlier alteration of transcripts in 
masseter and diaphragm might be explained by the fact that these muscles need to 
differentiate earlier during embryogenesis, to be mature at the time of birth to ensure survival.  
Nebulin was first detected in cardiac muscle by Kazmierski and co-workers in 2003. 
They noted that nebulin seemed to be less abundant in cardiac muscle, possibly explaining 
why cardiac nebulin had not been observed before (Kazmierski et al., 2003). In cardiac 
muscle the relative abundance of both transcripts had increased manyfold in 7-day-old mice. 
The level remained elevated in 14-day-old mice, after which it decreased to the level observed 
in neonatal and 4-day-old mice (Figure 14).  
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Figure 14. In cardiac muscle high abundance of the two transcripts are observed in 7- and 14-
day-old mice. After this the expression decreases to a lower level. 
 
 
In the previous study (Study II) on adult human cardiac muscle, only transcripts 
expressing exon 144 (exon 128 in mice) were observed. Although this is the more abundant 
transcript in 6-week-old mice, the mice express both transcripts. This might be explained by 
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the non-quantitative method used to detect the transcripts in the human samples. 
Alternatively, the amino acid sequences encoded by these transcripts might have slightly 
different functions in human and mouse muscles.  
The fibre type does not seem to have an influence on the transcript composition in 
mouse muscles, given that transcripts of extensor digitorum longus and tibialis anterior 
muscles composed mostly of fast fibres do not differ from gastrocnemius muscle consisting of 
both fast and slow fibres. Our previous work on human muscles is in concurrence with these 
results. Human tibialis anterior, rectus femoris and gastrocnemius consist of both fast and 
slow fibres but still yield different expression patterns of the transcripts studied.  
Alternative RNA splicing of myosin, tropomyosin, troponin T and dystrophin regulates 
gene expression during myocyte differentiation in vertebrate and invertebrate embryos 
(Bucher et al., 1999; George et al., 1989; Perry, 2001; Sironi et al., 2002). In the quadriceps 
muscle a transient increase of cardiac α-actin isoforms has been observed in mouse muscles. 
An simultaneous elevation of skeletal α-actin was noted in cardiac muscle. The α-actin  
expression characteristic of adult skeletal muscle was not observed until after 42 days 
postnatal in the mouse (Collins et al., 1997). Since actin and nebulin are in close proximity in 
the thin filament, there might be a connection between the reappearance of the two α-actin 
isoforms in skeletal and cardiac muscle and the expression pattern of transcripts expressing 
mouse exons 127 and 128 in skeletal muscle. We speculate that the amino acid sequences 
encoded by these exons harbour regulatory functions during muscle differentiation. In cardiac 
muscle the differences in the quantity of the transcripts might also be significant. This is 
indicated by the relative abundance of transcripts in 7- and 14-day-old cardiac muscle. 
 
2.4  NM-causing mutations in the nebulin gene, NEB (Study IV and unpublished data) 
 
 
The gene thought to be responsible for the majority of NM cases is NEB. To date, a total 
of 56 different mutations in 55 families with autosomal recessive inheritance have been 
identified in NEB. Five of these mutations were published by Pelin and co-workers in 1999, 
13 were included in study IV while the remaining 38 are unpublished. Thirteen of the 55 
families are Finnish and 42 are families from a number of other countries. The mutations 
identified are mainly compound heterozygous. Although the typical form of NM appears to be 
most common, all different subtypes of NM are represented among patients with mutations in 
NEB.  
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To date, in a significant proportion of NM patients screened for mutations in most of the 
NEB exons, only one of the predicted compound heterozygous mutations has been identified 
(Vilma-Lotta Lehtokari, personal communication). The methods used for detecting mutations 
in this gene have been single strand conformation polymorphism (SSCP) and denaturing high-
performance liquid chromatography (DHPLC). SSCP relies on a change in mobility of DNA 
strands in gels caused by conformational alteration. This method is not as accurate as DHPLC 
and some mutations, especially those substituting adenosine for other nucleotides, can go 
undetected (Yamanoshita et al., 2005). The semi-automated DHPLC is a method suitable for 
large sample sets. This method is based on the difference in electrophoretic mobilities of 
homo- and heteroduplexes formed between the wild-type and the mutated sequences (Oefner 
and Underhill, 1995). The limitation of this method is the specificity, estimated to be 
approximately 85 % (Yamanoshita et al., 2005) and that large deletions, such as the 2502 bp 
deletions observed in the Ashkenazi Jewish population, might not be detected (Vilma-Lotta 
Lehtokari, personal communication). Although some of the nebulin mutations might have 
gone undetected with these methods it seems unlikely that that those would account for a high 
proportion of NM mutations.  
The high number of splice-site mutations in NEB that typically affect the invariant 
splice-site sequences indicate that some of the mutations not yet identified could be located in 
variant splice-site sequences. It is also possible that some of the mutations predicted to be 
polymorphisms in fact cause aberrant splicing.  
Most of the mutations detected to date cause frameshifts due to insertions or deletions. 
Nonsense mutations predicted to result in truncated or internally deleted proteins are also 
common. Of all identified mutations in NEB, 30% are splice site mutations, most of which 
affect the GT and AG dinucleotides at the exon-intron junctions (Vilma-Lotta Lehtokari, 
personal communication). A considerable proportion, estimated to be between 10-15%, of 
disease-causing mutations in human genes affect pre-mRNA splicing (Cartegni et al., 2002; 
Krawczak et al., 1992), Human Gene Mutation Database: 
http://archive.uwcm.ac.uk/uwcm/mg/hgmd/search.html. These include mutations in the 
invariant splice-site sequences, i.e. the GT and AG intronic dinucleotides at the 5´ (donor) and 
the 3´ (acceptor) exon-intron junctions. Mutations in these nucleotides completely eradicate 
exon recognition. This is the case in the severe Menkes disease, caused by a mutation at the 
donor splice-site of exon 6 in the ATP7A gene (Moller et al., 2000). In these cases the 
mutation is believed to cause a complete absence of correctly spliced transcripts. Other 
mutations affecting splicing comprise mutations in less conserved, variant consensus motifs, 
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adjacent to both donor and acceptor sites (Hastings and Krainer, 2001; Padgett et al., 1986; 
Smith and Valcarcel, 2000) and mutations in introns that generate cryptic donor or acceptor 
sites and can lead to partial inclusion of intronic sequences. These mutations can permit 
production of both aberrantly and correctly spliced transcripts, by either weakening or 
strengthening exon-recognition motifs. This is the case with occipital horn syndrome (OHS), 
allelic to Menkes disease, also caused by a mutation in the ATP7A gene. The OHS mutation is 
a 3-bp deletion that affects a variant sequence motif of the same donor site, i.e. exon 6 
donor-site. This leads to incomplete exon skipping and is associated with the milder OHS 
disorder (Moller et al., 2000).    
Missense mutations in NEB appear to be a rare cause of NM. No obvious mutational 
hotspots have been observed although three mutations have been identified in exon 171 in 
four unrelated patients. All these mutations cause a frameshift and a premature stop at the 
same codon. In exon 163 an insertion and a deletion also causing a frameshift and a premature 
stop codon have been identified in two unrelated patients. In exon 180 three mutations, all 
with different outcomes, have been identified in three unrelated patients (Table 3). One of 
these mutations is a homozygous 1–bp deletion, causing a premature stop codon in one of the 
patients. This mutation resembles a mutation previously identified by Pelin and co-workers 
(1999), believed to encode nebulin lacking the serine-rich domain and the SH3-domain in the 
carboxy-terminal end of the molecule. Both these domains are highly conserved between 
species and are believed to have important roles in the formation of Z-discs (Millevoi et al., 
1998; Politou et al., 2002).  
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Table 3. Eighteen NEB mutations identified in the last 42 exons of the gene. Families where 
patients have homozygous mutations are indicated with an asterisk. The first mutations in 
NEB identified in families 1-5 have been published (Pelin et al., 1999). 
Family Mutation Location Predicted effect Control chrom.
1 del(G) Exon 156 Frameshift, stop at codon 5850 0/242
2 ins(GTTT) Exon 163 Frameshift, stop at codon 6123 0/216
3 del(AG) Exon 163 Frameshift, stop at codon 6123 0/216
del(GA) Exon 177 Frameshift, stop at codon 6391 0/226
4* G to C Exon 154 Abnormal splicing of exon 154 0/236
5* G to T Exon 181 Nonsense, stop at codon 6636 0/238
6 C to T Exon 148 Nonsense, stop at codon 5564 0/236
del(GTTCCAGAA) Exon 147 Abnormal splicing of exon 147 0/204
7 A to C Exon 151 Missense, threonine to proline (T5681P) 0/210
8 A to C Exon 151 Missense, threonine to proline (T5681P) 0/210
9 C to G Exon 152 Nonsense, stop at codon 5689 0/206
10 T to C Intron 156 Abnormal splicing of exon 156 0/242
11 del(CA) Exon 164 Frameshift, stop at codon 6154 0/284
12 dup(TCAA) Exon 171 Frameshift, stop at codon 29 in 171 0/226
13 dup(CAAA) Exon 171 Frameshift, stop at codon 29 in 171 0/226
14* dup(CAAA) Exon 171 Frameshift, stop at codon 29 in 171 0/226
15* del(AG) Exon 171 Frameshift, stop at codon 29 in 171 0/226
16 T to G Exon 180 Nonsense, stop at codon 6523 0/292
17 del(AT) Exon 180 Frameshift, stop at codon 6512 0/292
18* del(T) Exon 180 Frameshift, stop at codon 6525 0/220
 
 
 
Among the Finnish patients a missense mutation in exon 151 changing threonine to 
proline appears common (Vilma-Lotta Lehtokari, personal communication). This is probably 
a consequence of the Finnish population history and it seems likely that this mutation has 
arisen in a common ancestor of these Finnish patients. The different ages of onset and clinical 
severity of two patients in one family suggests that the clinical presentation might be 
influenced by modifying factors. 
Several mutations have been identified in the alternatively spliced exons at the 3´end of 
the gene. The mutations affecting differentially expressed exons are predicted to affect muscle 
development by reducing nebulin isoform diversity. In patients with mutations in ACTA1 or 
TNNT1 genes, upregulation of cardiac and fetal actin and troponin is speculated to 
compensate for the loss of skeletal α-actin and troponin T1, respectively (Ilkovski et al., 2001; 
Jin et al., 2003; Sparrow et al., 2003). As different nebulin isoforms are expressed in muscles 
at differential developmental stages, a similar mechanism might explain some of the variation 
in age of onset in patients with NEB mutations. Patients with mutations in alternatively 
spliced exons are likely to express several normal isoforms. The use of alternative transcripts 
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may explain why severe phenotypes are rare among patients with two truncating NEB 
mutations. 
Point mutations in coding regions of genes have generally been assumed to exert their 
effects by altering single amino acids in the encoded protein. It is, however, becoming 
increasingly evident that many exonic nonsense, missense and even translationally silent 
mutations affect pre-mRNA splicing. These mutations can inactivate genes by inducing the 
splicing machinery to skip the mutant exon or alternatively create ectopic splice sites or 
activate cryptic splice sites, thereby changing the overall splicing pattern of the mutant 
transcript (Cartegni et al., 2002).  
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CONCLUSIONS AND FUTURE PROSPECTS 
 
 
Of the two genes studied in this work, NEB clearly plays the more important role in 
causing NM. It also constitutes a greater challenge than TPM2 because of its size. To date, 
only two NM-causing mutations have been identified in the β-tropomyosin gene. It is now 
well established that NM-causing mutations in this gene are rare. However, as tropomyosins 
have a central role in muscle contraction, the molecular background of these mutations is of 
interest, also because β-tropomyosin is expressed in a variety of non-muscle tissues not 
clinically affected by these mutations. In the future, recombinant wild-type and mutated 
β-tropomyosins can be used to test how these amino acid changes influence the actin-binding 
properties and tropomyosin dimer preference.    
NEB comprises 249 kb of genomic sequence, including regions that are highly 
homologous, making mutation detection in this gene laborious to say the least. Mutation 
screening of NEB exons and intron sequences flanking the exons have so far been conducted 
using SSCP and DHPLC, followed by sequencing of aberrant fragments. Although DHPLC 
seems to be more sensitive than SSCP, our results indicate that it does not identify all 
mutations. For a disorder like NM caused by mutations in at least five different genes, 
including the giant NEB, we are constantly searching for new, more sensitive methods for 
mutation detection. New methods are not only needed to speed up the identification of 
hitherto unknown disease-causing mutations, keeping in mind that most of the introns remain 
to be analysed, but also to make mutation detection more sensitive. Furthermore, a feasible 
method for detection of large deletions needs to be introduced into the mutation detection tool 
set.   
There are families not showing linkage to any of the five known NM genes. New 
causative genes are being sought in consanguineous families. We expect that mutations in 
ACTA1 and NEB will remain the major causes of NM and speculate that several new genes 
will be identified as rare causes of the disorder. 
Common to all known genetic alterations underlying NM are that they affect thin 
filament proteins, causing muscle weakness and the presence of nemaline bodies in the 
muscle fibres. Much work is needed to elucidate to what extent the pathogenetic pathways 
may be shared. To understand the pathogenetic mechanisms underlying NM caused by 
mutations in NEB we need to learn more about the role of nebulin in normal muscle. We 
know now that different muscles and muscles at different developmental stages express 
different mRNA transcripts both in mice and humans. The studies on alternative transcripts of 
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the nebulin gene illustrate the complexity of nebulin expression, suggesting that the overall 
expression of nebulin is likely to be intricate. Further investigations are needed to elucidate 
the function of the alternative transcripts encoding nebulin. To reveal the role of the amino 
acid sequences encoded by human exons 143 and 144 and the corresponding mouse exons, 
antibodies are required. Additionally, biochemical analyses, such as yeast two-hybrid 
screening, could provide some clues to possible molecular interactions with other proteins and 
maybe even to other genes causing the disorder. A possible connection between the 
expression pattern of nebulin exons 143 and 144 and the postnatal reappearance of α-cardiac 
actin in skeletal muscles and α-skeletal actin in heart muscle should be elucidated by, for 
example, quantitative real-time RT-PCR. 
Mouse models for ACTA1 and TPM3 mutations identified as causing NM in humans 
already exist. The work is in progress for making a mouse model for a NEB mutation found in 
homozygous form in a NM sib pair. We hope that these models will provide us with 
information that could help elucidate the pathogenetic mechanisms underlying NM, plan 
therapeutic strategies and perhaps guide us in the search for mutations among these genes.  
Due to the genetic heterogeneity molecular diagnostics of NM patients is challenging. 
Since only vague genotype–phenotype correlations have been observed in NM patients, 
ACTA1 is usually the first gene screened for mutations. If none are identified in this small 
gene, mutation screening is pursued in the giant NEB. Linkage analysis is conducted in 
suitable families after mutations in ACTA1 have been ruled out. The small size of ACTA1 
makes it easily available for routine diagnostics which is not, at present, feasble for NEB. As 
most mutations identified in ACTA1 have arisen de novo the recurrence risks are difficult to 
estimate, also making prenatal diagnosis complicated. In families with known mutations 
prenatal testing can be conducted.  
Designing gene therapy for NM would be a demanding task, given that most patients 
have their own mutations, and most ACTA1 mutations have arisen de novo. If gene therapy is 
planned for patients with ACTA1, TNNT1 and NEB mutations, up-regulation of alternative 
isoforms might be the key factor.  
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